Cinnamomum Species: Bridging Phytochemistry Knowledge, Pharmacological Properties and Toxicological Safety for Health Benefits

Javad Sharifi-Rad1,2*, Abhijit Dey3, Niranjan Koirala4, Shabnum Shaheen5, Nasreddine El Omari6, Bahare Salehi7, Tamar Goloshvili8, Nathália Cristina Cirone Silva9, Abdelhakim Bouyahya10*, Sara Vitalini11, Elena M. Varoni12, Miquel Martorell13,14*, Anna Abdolshahi15, Anca Oana Docea16, Marcella Iriti17, Daniela Calina17*, Francisco Les18,19*, Victor López18,19 and Constantin Caruntu20,21*

1Phytochemistry Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran, 2Facultad de Medicina, Universidad del Azuay, Cuenca, Ecuador, 3Department of Life Sciences, Presidency University, Kolkata, India, 4Department of Natural Products Drugs Discovery, Dr. Koirala Research Institute for Biotechnology and Biodiversity, Kathmandu, Nepal, 5Department of Botany, Lahore College for Women University, Lahore, Pakistan, 6Laboratory of Histology, Embryology and Cytogenetic, Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Rabat, Morocco, 7Medical Ethics and Law Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran, 8Institute of Botany, Plant Physiology and Genetic Resources, Ilia State University, Tbilisi, Georgia, 9Department of Food Science, Faculty of Food Engineering (FEA), University of Campinas (UNICAMP), Campinas, Brazil, 10Laboratory of Human Pathology Biology, Faculty of Sciences, Genomic Center of Human Pathology, Faculty of Medicine and Pharmacy, Mohammed V University of Rabat, Rabat, Morocco, 11Department of Agricultural and Environmental Sciences, Milan State University, Milan, Italy, 12Department of Biomedical, Surgical and Dental Sciences, Milan State University, Milan, Italy, 13Department of Nutrition and Dietetics, Faculty of Pharmacy, University of Concepcion, Concepcion, Chile, 14Universidad de Concepcion, Unidad de Desarrollo Tecnológico, UDT, Concepcion, Chile, 15Food Safety Research Center (isat), Semnan University of Medical Sciences, Semnan, Iran, 16Department of Toxicology, University of Medicine and Pharmacy of Craiova, Craiova, Romania, 17Department of Clinical Pharmacy, University of Medicine and Pharmacy of Craiova, Craiova, Romania, 18Department of Pharmacy, Faculty of Health Sciences, Universidad San Jorge, Zaragoza, Spain, 19Instituto Agroalimentario de Aragón-I2A (CITA-Universidad de Zaragoza), Zaragoza, Spain, 20Department of Physiology, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania, 21Department of Dermatology, “Prof. N.C. Paulescu” National Institute of Diabetes, Nutrition and Metabolic Diseases, Bucharest, Romania

The genus Cinnamomum includes a number of plant species largely used as food, food additives and spices for a long time. Different traditional healing systems have used these plants as herbal remedies to cure diverse ailments. The aim of this comprehensive and updated review is to summarize the biodiversity of the genus Cinnamomum, its bioactive compounds, the mechanisms that underlie the pharmacological activities and molecular targets and toxicological safety. All the data in this review have been collected from databases and recent scientific literature including Web of Science, PubMed, ScienceDirect etc. The results showed that the bioactive compounds of Cinnamomum species possess antimicrobial, antiadipic, antioxidant, anti-inflammatory, anticancer and neuropeptotrophic effects. The preclinical (in vitro/in vivo) studies provided the possible molecular mechanisms of these action. As a novelty, recent clinical studies and toxicological data described in this paper support and confirm the pharmacological importance of the genus Cinnamomum. In conclusion, the obtained results from preclinical studies and clinical trials, as well as reduced side effects provide insights
INTRODUCTION

The *Cinnamomum* plants have been studied for its phytoconstituents and pharmacological properties as well as traditional medicinal significance. *Cinnamomum verum*, known as the “true cinnamon tree” and “Ceylon cinnamon tree” is an evergreen small, tree that belongs to the Lauraceae family. Along with other cinnamon species, such as *Cinnamomum cassia*, *Cinnamomum verum* etc., the tree bark is used to obtain cinnamon (Ribeiro-Santos et al., 2017). The ancient botanical name of this tree – *Cinnamomum zeylanicum* - derives from Ceylon the old name for Sri Lanka (Ribeiro-Santos et al., 2017). *Cinnamomum cassia*, also called “Chinese cinnamon,” is an evergreen tree, native to South China; Chinese cinnamon being produced mainly in the southern regions and is also widely grown in the other areas of the South and East Asia (Bedigian, 2005). People used cinnamon obtained from a variety of *Cinnamomum* plants as a spice from ancient times. It is mentioned in the texts written in Sanskrit and in the Bible, as well as in the works of Herodotus and Pliny (Lu et al., 2011). In Egypt, *Cinnamomum zeylanicum* was used in the embalming process. It was also added to foods for preservation. Both in India and Europe, *Cinnamomum* species have been traditionally used in the treatment of respiratory viruses, especially combined with ginger (*Zingiber officinale*). Ginger stimulates blood circulation in the extremities (toes, fingers), and *Cinnamomum* plants are an alternative natural medicine for reducing muscle pain and other signs and symptoms of colds and flu. Other traditional uses include urinary tract infections, relieve the abdominal discomfort, and improves digestion, antidiabetic, analgesic, and neuroprotective effects (Ravindran et al., 2003).

All types of cinnamon contain the active ingredient cinnamaldehyde, which accounts for between 65 and 80% of the essential natural oil. Cinnamon is used in case of dyspepsia, flatulence, nausea, intestinal colic, slow digestion, diarrhea, and digestive atony. This antispastic effect is attributable to the natural chemical compound catechin that contributes to the reduction of nausea and vomiting. Also, its volatile oil can help better food processing by breaking down fat during digestion. The studies showed that cinnamon helps diabetic patients to metabolize sugar more easily. In the case of people with type II diabetes, the pancreas produces insulin, but their body cannot use it effectively for decreasing blood sugar concentration (Chen et al., 2012). The researchers have found in recent studies that cinnamon improves insulin’s ability to metabolize glucose, helping to control blood sugar levels. It contains the antioxidant glutathione and a type of flavonoid called methyl hydroxychalcone polymer (MHCP) (Qin et al., 2010). The potential antidiabetic mechanism of cinnamon is associated with increasing the receptivity of adipose cells to the hormone insulin that regulates the metabolism of glucose and controls the level of sugar in the blood.

Cinnamon helps reduce pain due to its action of inhibiting prostaglandin. Cinnamaldehyde acts against the coagulation of platelets in the blood, which can hinder blood flow. It inhibits arachidonic acid’s release (a trigger for the inflammatory response) from cell membranes (Vallianou et al., 2019). Therefore, cinnamon is useful for the pharmacotherapy of inflammatory diseases, such as rheumatoid arthritis (Rogoveanu et al., 2018; Shishebhor et al., 2018). Recent studies showed that the scent and aroma of cinnamon act as cognitive stimuli, which could improve memory, visual-motor capacity and virtual memory (Nussbaum et al., 2017), due to its compound cinnamic aldehyde. Experimental researches on rodents receiving cinnamic aldehyde have reported improvements in stress-induced depressive behaviors. Cinnamic aldehyde is administered orally in the treatment of behavioral and mental disorders. Recent findings in this regard may also be helpful in treating depression (Panickar et al., 2009).

Starting from the ethnopharmacological premises of the therapeutic beneficial effects of *Cinnamomum* genus, in this manuscript were highlighted, based on scientific evidence the potential current pharmacological mechanisms and human clinical studies for the benefits of human health. Therefore, this current work reviews the comprehensive and current knowledge on the phyto-constituents, potential mechanisms of the main pharmacological activities evidenced by preclinical studies (*in vivo, in vitro*), recent clinical trials and toxicological data regarding safety of *Cinnamomum* plants.

REVIEW METHODOLOGY

Scientific search engines Medline, PubMed, ScienceDirect and Scopus were searched to retrieve literature and cross-references using key words: “*Cinnamomum*,” “phytochemistry,” “pharmacology”; “mechanisms of action”; “toxicology.” We included literature in relation to the bioactive compounds, pharmacological activities and underlying mechanism of action, clinical studies, toxicological and safety considerations of different *Cinnamomum* species. Plants’ taxonomy was validated using The Plant List (http://www.thepantlist.org/), and chemical formulas were validated by consulting the PubChem chemical base data (http://pubchem.ncbi.nlm.nih.gov/search/#collection=compounds). Inclusion criteria: *in vitro*/*in vivo* pharmacological studies using cell lines and laboratory animals, studies involving extracts of the genus *Cinnamomum*, studies with obvious mechanisms of action. Exclusion criteria: studies that included homeopathic
preparations and other associated nutritional supplements, studies without explaining the mechanism of action.

**PHYTOCHEMISTRY OF CINNAMOMUM GENUS**

**Chemical Composition**

The chemical composition of cinnamon EOs (essential oils) varies depending on several factors that include the part of the plant used, growing season, age of trees, location, and extraction methods (Kaul et al., 2003; Barceloux, 2009; Wang et al., 2009; Chakraborty et al., 2015). Cinnamaldehyde and its analogs, butanolides, diterpenoids, lignans and several other compounds, are present in this genus. From the genus *Cinnamomum*, a total of 127 chemical compounds have been identified (Zhao and Ma, 2016).

Cinnamon presents a diversity of resinous compounds, including cinnamaldehyde, cinnamates, cinnamic acid and natural EOs (Senanayake et al., 1978) (Figure 1; Table 1). Over time, cinnamaldehyde changes color, absorbs oxygen and thus explains the appearance of the perfume and spicy taste (Singh et al., 2007). EOs contain a great variety of volatile natural compounds, such as trans-cinnamaldehyde, eugenol, cinnamyl acetate, L-borneol, β-caryophyllene, caryophyllene oxide, L-bornyl acetate, a-thujene, a-terpineol, a-cubebe, terpinolene and E-nerolidol (Jantan and Goh, 1992; Jantan et al., 2003; Jantan et al., 2005; Chua et al., 2008; Abdelwahab...
TABLE 1 | The most representative chemical compounds of Cinnamomum plants.

| Plant parts | Compounds                                      | Ref                      |
|-------------|------------------------------------------------|--------------------------|
| Bark        | cinnamaldehyde 65–80% eugenol 5–10%            | Yanakiev. (2020)         |
| Bark of root| camphor 58%                                     | Rao and Gan. (2014)      |
| Leaf        | eugenol 70–80%, cinnamaldehyde 1–8%            | Utchanyakiat et al. (2016)|
| Fruits      | trans-cinnamyl acetate 40–50% caryophyllene 10–15% | Bakar et al. (2020)      |
| Buds        | α-bergamotene 27% terpene hydrocarbons 80% α-copaene 20%, terpenoids 10% | Barceloux. (2009)       |
| Flowers     | trans-cinnamyl acetate 40% trans-α-bergamotene 10% caryophylleneoxide 8% | Bakar et al. (2020)      |

et al., 2010; Tung et al., 2010; Geng et al., 2011). Spathulenol was reported as the major compound in leaf oil of *Cinnamomum alitissimum* Kosterm (Jantau et al., 2003).

According to (Wang et al., 2009), eugenol (80%) is the main volatile compound in the EO of *Cinnamomum verum* J. Presl (synonym: *Cinnamomum zeylanicum* Blume) instead of trans-cinnamaldehyde (16.25%) and the other constituents such as: alcohols, aldehydes, ketones, alkanes, sulfides, and ethers. The chemical composition in the bark and leaf EOs of *C. verum* consists of high levels of eugenol (90.2%) and cinnamaldehyde (44.2%). The chemical constituents of *C. verum* bark EO include three major compounds and six minor chemical derivatives (Yang et al., 2012). Cinnamaldehyde (59%), benzaldehyde (12%) and eugenol (5%) are the major compounds, while the six minor constituents are α-phellandrene (1.1%), linalool (1.1%), benzoic acid (0.8%), β-caryophyllene (0.7%), linalyl acetate (0.6%) and benzyl cinnamate (0.6%). The most important compounds identified in the leaf oil of *C. verum* grown are eugenol (75%), linalool (8%) and piperitone (2.5%) (Raina et al., 2001).

Chemical constituents in the leaf EO of *Cinnamomum burmanni* (Nees & T. Nees) Blume are trans-cinnamaldehyde (60%), eugenol (18%) and coumarin (14%). Other constituents identified in the oils are alcohols, aldehydes, and ketones. The major components in the stem bark oil of *Cinnamomum iners* (Reinw. ex Nees & T. Nees) Blume are 1,8-cineole (41%), α-terpineol (15%) and terpinen-4-ol (14%). The other components identified are β-pinene (4.75%), γ-terpinolene (1.61%) and caryophyllene oxide (4.37%) (Wang et al., 2009).

Other minor constituents reported in cinnamom EO include: cinnamic acid, phenolic acids, oligomeric procyanidins, pentacyclic diterpenes, cinnzeylan, and its acetyl derivative cinnzeylanine, mannitol, xylose, arabinose, xylanose, glucose, mucilage polysaccharides (European Scientific Cooperative on Phytotherapy, 2003). Several nonvolatile compounds have been found in cinnamom EOs such as cinnamiscins, cinnzeylan, cinnzeylanin, anhydrocinnzeylan, anhydrocinnzeylanin, several benzyl isoquinoline alkaloids, cinnamic acid, β-sitosterol, flavanol glucosides, coumarin, protocatechuic acid, vanillic acid and syringic acid (Leela, 2008).

**Cinnamomum’s Natural Compounds: Pharmacokinetics, Bioavailability, Bioactivity and Metabolism**

Considering the pharmacokinetics, bioavailability and metabolism of Cinnamomum active ingredients, very little works have been performed. Many studies described the role of bioactive compounds from the plants in enhancing bioavailability of some standard drugs (Salehi et al., 2020b).

Pharmacokinetics of cinnamic acid (CA) indicated the CA was readily absorbed and then metabolized quickly into hippuric acid (HA) when a decoction of Ramulus Cinnamomi (RC) [containing CA 7.62 × 10⁻⁵ mol/kg and cinnamaldehyde (CNMA) 1.77 × 10⁻⁵ mol/kg] was administered in rats via oral route. CNMA was found to be metabolized partially in stomach and small intestine into CA and almost fully metabolized in liver into CA before being absorbed into rat blood. The results indicated that plasma CA in RC group probably came from CNMA transformation in RC (Chen et al., 2009). Cinnamon also increased pioglitazone bioavailability via CYP3A4 enzyme inhibition in rats following oral administration owing to its possible use in combination with pioglitazone against diabetes (Mamindla et al., 2017). CA significantly inhibited rosuvastatin (RSV) (a specific breast cancer resistance protein) transport into rat bile thus enhanced the plasma exposure of the same (Basu et al., 2013).

In a recent study, comparative pharmacokinetic analysis of *Cinnamomum cassia* twigs’ standard decoction and dispensing granules containing three phenolics such as cinnamic acid, vanillic acid and protocatechuic acid in rats revealed the AUC₀₋₅ values of the compounds by LC-MS/MS (Tao et al., 2019).

**PRECLINICAL STUDIES RELATED TO PHARMACOLOGICAL ACTIVITIES AND POTENTIAL MECHANISMS OF CINNAMOMUM’S PHYTO-CONSTITUENTS**

Various traditional uses of *Cinnamomum* plants motivated a series of experimental investigations of the plant’s pharmacological properties (Wang et al., 2020). Those experimental approaches tempted to validate the potential uses of these plants as therapeutic remedies. Studies have been reported on extracts and isolated compounds of *Cinnamomum* plants, investigating antibacterial, anti-diabetes, anti-inflammatory, antioxidant, antitumor, and neuroprotective properties.

**Antibacterial Activity**

In order to inhibit the growth and proliferation of pathogenic microorganisms, synthetic drugs have been commonly used for...
the treatment of microbial infections. The overuse of conventional antibacterial drugs could lead to serious side effects, including the selection of resistant bacterial strains and the development of antibiotic resistance during treatment, posing a real threat to global public health (Russell, 2002; Goyal et al., 2008; Călinescu et al., 2017; Ungureanu et al., 2017; Zlatian et al., 2018). Therefore, it is necessary to discover new sources of antibiotics such as natural antimicrobial compounds that could be an effective and cheaper alternative (Mbwambo et al., 2007; Salehi et al., 2019a).

The mechanisms underlying the antibacterial effects of natural derivatives of Cinnamomum plants are complex. Cinnamaldehyde, as well as eugenol, inhibited β-lactamase’s production by the bacterium and destroyed its cell wall (Helander et al., 1998; Di Pasqua et al., 2007). Phenolic compounds such as carvacrol can also cause destruction of the cell cytoplasmic membrane (Ultee et al., 1999), and terpenes interact with the bacterial membrane by modifying its permeability (Lambert et al., 2001) and increasing the penetration of antibacterial agents. Essential oils of Cinnamomum contain a wide range of different groups of chemical compounds, suggesting that their antibacterial activity might have several mechanisms (Skandamis and Nychas, 2001; Carson et al., 2002). (Figure 2).

A recent study highlighted that MBC (minimum bactericidal concentration) and MIC (minimum inhibitory concentration) of the methanol extract of C. burmanni leaves were 625 and 2,500 μg/ml, against Bacillus cereus. For other bacterial strains (Staphylococcus aureus, Listeria monocytogenes, Escherichia coli, and Salmonella anatum), the values are >2,500 μg/ml for both concentrations (Shan et al., 2007).

The methanol extract of Cinnamomum tamala (Buch.-Ham.) T. Nees & Eberm. stem bark revealed MIC values of 256, 4,096, 4,096, and 2048 μg/ml against Staphylococcus aureus, Streptococcus pyogenes, B. cereus and Bacillus subtilis, respectively, with inhibition diameters ranging from 14.0 to 20.8 mm (Goyal et al., 2009). The aqueous extract of C. verum bark demonstrated antibacterial activity against Moraxella catarrhalis with MIC and MBC values of 120 and 240 mg/ml, respectively, and an inhibition zone of 11 mm (Rasheed and Thajuddin, 2011). (Table 2).

Regarding the EO of C. osmophloeum leaves, the MIC values were 200 and 500 μg/ml for the 9 bacteria tested (Chang et al., 2001), and the chemical components of this oil were similar to...
those of *Cinnamomum cassia* (L.) J. Presl (Hu et al., 1985). In addition, (Oussalah et al., 2006) evaluated the antibacterial efficacy of essential oils of two *Cinnamomum* species: *C. cassia* and *C. verum* against *Pseudomonas putida* and found MIC values of 0.05 and 0.1 % wt/vol, respectively. In another study, the MIC values for the EO of *C. cassia* leaves were 500 ppm for *E. coli*, *B. cereus*, *Lactobacillus sakei* and 750 mg/ml for *Salmonella typhimurium* (Turgis et al., 2012).

The antibacterial potency of the methanol extract of *C. cassia* was also tested against different species of *E. coli* by the disk diffusion method and the microdilution (Kim et al., 2004). The *C. cassia* bark EO was tested on *L. monocytogenes* and EPEC with a zone of inhibition of 22.42 and 13.72 mm, respectively, and a MIC of 0.03 and 0.06 μg/ml respectively (de Oliveira et al., 2012). Another study on the same part of *C. cassia* investigated the permeability of the bacterial membrane by measuring the relative electrical conductivity, which increased with the increased concentration of the EO (Huang et al., 2014).

The antimicrobial property of *C. verum* EO was assayed against 21 bacteria strains, using MIC methods and disk diffusion. The EO highlighted the significant antibacterial activity against the tested strains. It showed higher activity against Gram-positive (*Enterococcus, Streptococcus, Staphylococcus*) and Gram-negative (*Pseudomonas aeruginosa*) bacteria strains. These results are consistent with those of Chao et al. (2000) revealing that bark oil of cinnamon completely inhibited the growth of selected Gram-negative and Gram-positive bacteria.

*In vitro* antibacterial efficacy of different EOs (Al-Bayati and Mohammed, 2009; Noudeh et al., 2010; Guerra et al., 2012; Utcharyiakiet et al., 2016) and methanol extracts (Hameed et al., 2016) of *C. verum* bark was evaluated against Gram-positive and Gram-negative bacteria using broth dilution and diffusion methods. The obtained results showed that *C. verum* bark EO was able to inhibit all of the tested strains. Furthermore, the main chemical constituents of *C. cassia* and *C. verum* natural oils were eugenol cinnamaldehyde (Ross, 1976; Hu et al., 1985) which could inhibit microbial growth (Lee and Ahn, 1998; Ooi et al., 2006).

EOs of *Cinnamomum microcanthum* f. kanehirae (Hayata) S. S. Ying (leaves and twigs) were effective against *Vibrio parahemolyticus*, *V. alginolyticus*, *V. vulnificus*, *Lactococcus garvieae*, *Debaryomyces Hansenii*, *Photobacteria damsel*, *Streptococcus sp.* and *Aeromonas hydrophila*, with diameters reduction from 0.1 to 1 cm (Yeh et al., 2009). The observed difference may be due to the difference of antibacterial constituents in leaves and twigs. The antibacterial screening of EO samples extracted from *Cinnamomum bejolghota* (Buch.-Ham). Sweet was evaluated using disc diffusion assay against zoonotic enteropathogens and showed promising antibacterial activity (Wannissorn et al., 2005). Indeed, EOs are complexes of antibacterial agents including natural aromatic and volatile compounds (Loy et al., 2001).

The volatile oils and extracts from the stem bark of *Cinnamomum impressicostatum* Kosterm., *C. altissimum* and *C. porrectum* (Roxb.) Kosterm showed high antibacterial activity against Gram-positive and Gram-negative bacteria, including methicillin-resistant *Staphylococcus aureus* (MRSA). Some tested extracts exhibited relevant activity against MRSA compared with methicillin-sensitive *S. aureus* (MSSA). The highest inhibition zone (21.0 mm) was measured for *C. impressicostatum* stem-bark water extract against MRSA with MIC and MBC values of 19.5 and 39.0 μg/ml, respectively (Buru et al., 2014). The leaf oil of *Cinnamomum chemungianum* M. Mohanan and A. N. Henry enhanced a moderate activity against the tested bacteria (Rameshkumar et al., 2007).

Agarwal et al. (2019) used *C. tamala* leaf extract to synthesize eco-friendly zinc oxide nanoparticles with important antibacterial effects against *S. aureus*. Authors showed that these nanoparticles induced reduction in bacterial growth, in a time and concentration-dependent pattern, due to membrane damage that leads to leakage of intracellular proteins and cellular contents. On the other hand, *C. verum* EOs exhibited remarkable inhibitory effects of *Staphylococcus aureus* multi-drug resistant (MDR). Indeed, cinnamon oil at concentrations of 3.12% strongly inhibited all the *Streptococcus mutans* isolated with the MIC values of 12.8–51.2 and 64–256 mg/ml, respectively (Fani and Kohanteb, 2011). (Rossi et al., 2019) showed that *C. verum* EOs inhibited the adhesion of *Salmonella enterica* which involved the reduction of polyphenol oxidase activity. (Wu et al., 2019) showed that *C. camphora* EOs had an important antibacterial potency against *E. coli* with a MIC and MBC of 200 μg/L.

(Yap et al., 2015) have studied the EO of *C. verum* bark against *E. coli* by testing the permeability of its outer membrane, and they found that the observed membrane damage was determined by denaturation and acidification of the cell membrane (Borges et al., 2013). This suggested that the EO of *C. verum* bark disrupts the cell membrane at lethal and sub-lethal concentrations by increasing the availability of the antibiotic in the bacterial cell (Eunikeb et al., 2012). Indeed, EOs are complexes of antibacterial agents including natural aromatic and volatile compounds (Loy et al., 2001).

**Antidiabetic Activities**

Diabetes mellitus is a chronic disease that affects about 7% of the world’s people (Zimmet et al., 2001) and it is expected to increase by 5.5% in 2025 (King et al., 1998). Diabetes mellitus type 2 (T2DM) accounts for 85–90% of all diagnosed diabetic patients (Wild et al., 2004) with high medical and social costs. Diabetes mellitus is characterized by an altered metabolism (of carbohydrates, lipids, and lipoproteins) and chronic hyperglycemia resulting from pancreatic β-cell dysfunction (Wild et al., 2004; Qin et al., 2010), insulin production deficiency, insulin resistance in key target tissues and impaired glycemic index control (Leiter and Lewanczuk, 2005), (DeFronzo et al., 1992). These alterations cause severe complications in the functioning of the cardiovascular system, as well as hypertension and dyslipidemia that are risk factors for stroke and myocardial infarction (Luscher and Steffel, 2008). Postprandial glucose control is essential for treating diabetes mellitus and avoiding its complications (Ortiz-Andrade et al., 2007). Moreover, correct diet and sport are necessary for the prevention of T2DM (Kahn et al., 2006; Hu, 2011).
### TABLE 2 | Preclinical pharmacological activities of *Cinnamomum* genus.

| Pharmacological activity | Cinnamomum plant extracts/ fractions | Methods | Models cellular lines (in vitro)/animal (in vivo) | Effects/underlying mechanisms | Ref |
|-------------------------|-------------------------------------|---------|-------------------------------------------------|-----------------------------|-----|
| **Antimicrobial**        |                                     |         |                                                 |                             |     |
| Cinnamomum altissimum/stem bark/EOs | Disk diffusion | MRSA | IC<sub>50</sub> = 12.0 mm (bacterial growth) |                             | Buru et al. (2014) |
| Cinnamomum umbjoeighota/leaves/EOs | Disk diffusion | MRSA | IC<sub>50</sub> = 156.25 μg/ml (bacterial growth) |                             | Wannisorn et al. (2005) |
| Cinnamomum cassia/leaves/EOs | Microdilution | Listeria monocytogenes | IC<sub>50</sub> = 500 μg/ml |                         | Dussalah et al. (2006) |
| Cinnamomum cassia/stem bark/EOs | Disk diffusion | Bacillus subtilis | IC<sub>50</sub> = 10 mg/ml |                         | de Oliveira et al. (2012) |
| Cinnamomum cassia/bark/EOs | Microdilution | Escherichia coli | IC<sub>50</sub> = 20 mg/ml |                         | Huang et al., 2014 |
| Cinnamomum chernangianum leaves/EOs | Disk diffusion | Staphylococcus aureus | IC<sub>50</sub> = 7 mm |                         | Ramesh Kumar et al. (2007) |
| Cinnamomum mirm prescocostatum stem bark/VO | Disk diffusion | MRSA | IC<sub>50</sub> = 156.3 μg/ml |                         | Buru et al. (2014) |
| Cinnamomum iners stem bark/VO | Disk diffusion | MRSA | IC<sub>50</sub> = 625.0 μg/ml (bacterial growth) |                         | Buru et al. (2014) |
| Cinnamomum longepaniculatum leaves/VO | Microdilution | Staphylococcus aureus | IC<sub>50</sub> = 6.3 μL/mL |                         | Li et al. (2014) |
| Cinnamomum micranthum leaves/EOs | Diffusion method | Vibrio parahaemolyticus | IC<sub>50</sub> = 2 mm |                         | Yeh et al. (2009) |
| Cinnamomum micranthum twig/EOs | Diffusion method | Vibrio parahaemolyticus | IC<sub>50</sub> = 5 mm |                         | Chang et al. (2001) |
| Cinnamomum osmophloeum leaves/EOs | Microdilution | Enterococcus faecalis | IC<sub>50</sub> = 250 μg/ml |                         | Chang et al. (2008) |

(Continued on following page)
| Pharmacological activity                  | Cinnamomum plant/extracts/fractions | Methods                  | Models cellular lines (in vitro/animal (in vivo)) | Effects/underlying mechanisms | Ref                          |
|------------------------------------------|-------------------------------------|--------------------------|---------------------------------------------------|------------------------------|------------------------------|
|                                          | Cinnamomum verum bark/EOs           | Microdilution            | Staphylococcus aureus                             | IC₅₀ = 0.55 mg/ml            | Unlu et al. (2010)           |
|                                          |                                     |                          | Streptococcus pyogenes                            | IC₅₀ = 0.55 mg/ml            |                              |
|                                          |                                     |                          | Escherichia coli                                 | IC₅₀ = 0.04 mg/ml            |                              |
|                                          |                                     |                          | Klebsiella pneumoniae                             | IC₅₀ = 0.14 mg/ml            |                              |
|                                          |                                     |                          | Proteus mirabilis                                 | IC₅₀ = 0.14 mg/ml            |                              |
|                                          |                                     |                          | Pseudomonas aeruginosa                            | IC₅₀ = 0.028 mg/ml           |                              |
|                                          |                                     |                          | Salmonella typhimurium                             | IC₅₀ = 0.14 mg/ml            |                              |
|                                          |                                     |                          | Mycobacterium smegmatis                           | IC₅₀ = 0.07 mg/ml            |                              |
|                                          |                                     |                          | Clostridium perfringens                           | IC₅₀ = 0.12 mg/ml            |                              |
|                                          |                                     |                          | Listeria innocua                                  | IC₅₀ = 0.05 mg/ml            |                              |
|                                          |                                     |                          | Listeria welshimeri                               | IC₅₀ = 0.28 mg/ml            |                              |
|                                          |                                     |                          | Listeria seeliger                                 | IC₅₀ = 0.56 mg/ml            |                              |
|                                          | Cinnamomum verum bark/aqueous       | Disk diffusion            | Moraxella catarrhalis                             | IC₅₀ = 1.1 mg/ml             | Rasheed and Thajuddin. (2011)|
|                                          |                                     | Microdilution            | Moraxella catarrhalis                             | IC₅₀ = 120 mg/ml             | Utchariyakiat et al. (2016) |
|                                          | Cinnamomum verum bark/EOs           | Microdilution            | Proteus mirabilis                                 | IC₅₀ = 0.1125 mg/ml          | Hameed et al., (2016)        |
|                                          |                                     |                          | Pseudomonas aeruginosa                            | 4 mm                        |                              |
|                                          |                                     |                          | Klebsiella pneumonia                              | 6 mm                        |                              |
|                                          |                                     |                          | Staphylococcus aureus                             | 5 mm                        |                              |
|                                          |                                     |                          | Acinetobacter spp.                                | IC₅₀ = 0.2 mg/ml             | Guerra et al., (2012), Noudieh et al., (2010) |
|                                          |                                     |                          | Staphylococcus aureus                             | IC₅₀ = 0.3 mg/ml             |                              |
|                                          |                                     |                          | Bacillus subtilis                                 | IC₅₀ = 0.04 mg/ml            |                              |
|                                          |                                     |                          | Escherichia coli                                 | IC₅₀ = 0.1 mg/ml             |                              |
|                                          |                                     |                          | Pseudomonas aeruginosa                            | IC₅₀ = 0.2 mg/ml             |                              |
|                                          |                                     |                          | Agrobacterium fumefaciens                         | IC₅₀ = 12.5 mg/ml            |                              |
|                                          |                                     |                          | Staphylococcus aureus                             | 17.2 mm                     | Al-Bayati and Mohammed, (2009)|
|                                          |                                     |                          | Bacillus cereus                                   | 18.3 mm                     |                              |
|                                          |                                     |                          | Escherichia coli                                 | 15.7 mm                     |                              |
|                                          |                                     |                          | Proteus mirabilis                                 | 15.2 mm                     |                              |
|                                          |                                     |                          | Klebsiella pneumonia                              | 17.5 mm                     |                              |
|                                          |                                     |                          | Pseudomonas aeruginosa                            | 14.5 mm                     |                              |
|                                          |                                     |                          | Staphylococcus aureus                             | IC₅₀ = 1.2 μg/ml             |                              |
|                                          |                                     |                          | Bacillus cereus                                   | IC₅₀ = 1.2 μg/ml             |                              |
|                                          |                                     |                          | Escherichia coli                                 | IC₅₀ = 1.2 μg/ml             |                              |
|                                          |                                     |                          | Proteus mirabilis                                 | IC₅₀ = 125.0 μg/ml           |                              |
|                                          |                                     |                          | Klebsiella pneumonia                              | MIC = 62.5 μg/ml             |                              |
|                                          |                                     |                          | Pseudomonas aeruginosa                            | MIC = 125.0 μg/ml            |                              |
|                                          |                                     |                          | Escherichia coli                                 | wall cell permeability       | Yap et al. (2015)           |
|                                          |                                     |                          |                                                   |                              |                              |

(Continued on following page)
TABLE 2 | (Continued) Preclinical pharmacological activities of Cinnamomum genus.

| Pharmacological activity | Cinnamomum plant/extracts/fractions | Methods | Models cellular lines (in vitro)/animal (in vivo) | Effects/underlying mechanisms | Ref |
|--------------------------|-------------------------------------|---------|-----------------------------------------------|-------------------------------|-----|
| **Antidiabetic**          |                                     |         |                                               |                               |     |
| *In vitro studies*        |                                     |         |                                               |                               |     |
| Cinnamomum verum bark/aqueous | α-amylase, α-glucosidase inhibition |         | IC_{50} = 0.5, 1.25, 2.5 mg/ml                 |                               | Ranila et al. (2010) |
| Cinnamomum verum bark/methanol | Yeast α-glucosidase, rat-intestinal α-glucosidase inhibition |         | IC_{50} = 5.83 μg/ml                           |                               | Shihabudeen et al. (2011) |
| Cinnamomum cassia (L.) J. Presl/Bark/ acetone and aqueous | Glucosidase, sucrase, maltase inhibition |         | IC_{50} = 670 μg/ml                            |                               | Kang et al. (2014) |
| Cinnamomum cassia (L.) J. Presl/Bark/ aqueous | PTP1B, α-glucosidase, α-amylase inhibition |         | IC_{50} = 1500 μg/ml                           |                               | Lin et al. (2016) |
| *In vivo studies*         |                                     |         |                                               |                               |     |
| Cinnamomum burmannii (nees and T. Nees) blume/bark/aqueous | Rats: very high fat diet induced hyperglycemia, 500, 300 mg/b.w.; oral |         | FBG, dose dependent manner                     |                               | Cheng et al. (2012) |
| Cinnamomum cassia (L.) J. Presl/bark/ aqueous | Rats: glucose 2 g/kg b.w.; ip; 85.7 mg/b.w oral |         | blood glucose control                          |                               | Verspohl et al. (2005) |
| Cinnamomum cassia (L.) J. Presl/ aqueous | Mice/STZ induced diabetes; 100 mg/kg/day; oral |         | blood glucose                                  |                               | Chen et al. (2013) |
| Cinnamomum cassia (L.) J. Presl/Bark/ Methanol | Mice/STZ induced diabetes; 200 mg/b.w.; oral |         | blood glucose                                  |                               | Kim et al. (2006) |
| Cinnamomum cassia (L.) J. Presl bark/ aqueous | Rats: alloxan induced diabetes 60 mg/b.w.; oral |         | blood glucose                                  |                               | Kambie and Rambhimaiah, (2015) |
| Cinnamomum porrectum bark/ polyphenols rich extract | Rats/STZ induced diabetes 100,200,300 mg/b.w.; oral |         | blood glucose                                  |                               | Jia et al. (2009) |
| Cinnamomum tamala leaves/ethanol | Rats: alloxan induced diabetes; 500 mg/b.w.; oral |         | blood glucose                                  |                               | Kar et al. (2003) |
| Cinnamomum tamala leaves/ essential oil | Rats: STZ induced diabetes 10, 200 mg/b.w.; oral |         | blood glucose                                  |                               | Kumar et al. (2012) |
| Cinnamomum verum bark/water-soluble polyphenols | Rats/STZ induced diabetes 200 mg/kg, oral |         | weight loss                                    |                               | Krishnakumar et al. (2014) |
| Cinnamomum verum bark/volatile oil | Rats/STZ induced diabetes 20 mg/kg; oral |         | plasma glucose                                  |                               | Subash Babu et al. (2007) |
| Cinnamomum verum essential oil | Rats/STZ induced diabetes 20 mg/kg; oral |         | blood glucose                                  |                               | Ali-Logmanil and Zari, (2009) |
| Cinnamomum verum stem bark/ chloroform | Rats/STZ induced diabetes 20 mg/kg; oral |         | muscle glycogen                                |                               | Anand et al. (2010) |
| Cinnamomum verum bark/volatile oil | Rats/alloxan induced diabetes 5, 10, 20 mg/kg; oral |         | FBG, dose-dependent manner                     |                               | Mishra et al. (2010) |
| Cinnamomum verum bark/volatile oil | Rats/alloxan induced diabetes 5, 10 and 20 mg/kg; oral |         | glucose, dose dependent manner                 |                               | Rajbir et al. (2009) |
| Cinnamomum verum sticks/Aqueous | Rats/STZ induced diabetes 3, 30 and 100 mg/kg; oral |         | blood glucose                                  |                               | Shen et al. (2010) |
| Cinnamomum verum bark/aqueous | Rats/oral glucose tolerance test 0.2 ml/day; rat |         | glycemic levels                                 |                               | Kannappan et al. (2008) |
| Cinnamomum verum bark/methanol | Rats/STZ induced diabetes 300 mg/kg; oral |         | |                               | Shihabudeen et al. (2011) |
| **Anti-inflammatory**     |                                     |         |                                               |                               |     |
| *In vitro studies*        |                                     |         |                                               |                               |     |
| Cinnamomum cassia/cinnam aldehyde | RAW 264.7, LPS stimulated mice macrophages |         | IC_{50}, 0, 6.25, 12.5, 25, 50 μM anti-inflammatory |                               | Liao et al. (2012a) |
| Cinnamomum camphora total crude extract/80% methanol, hexane, ethyl acetate fractions | RAW 264.7, LPS stimulated mice macrophages |         | IC_{50}, 100 μg/ml anti-inflammatory            |                               | Lee et al. (2006) |
| *In vivo studies*         |                                     |         |                                               |                               |     |
| Cinnamomum cassia bark oil/ cinnamaldehyde | Rats |         | dose = 2–6 mg/kg bw                            |                               | Chua et al. (2008) |
| Cinnamomum cassia cinnamic aldehyde | Mice/carrageenan induced paw edema |         | dose = 1.25, 2.5, 5 mg/kg/bw \ Anti-inflammatory |                               | Liao et al. (2012a) |
| (Continued on following page) | | | | | |
### TABLE 2 | (Continued) Preclinical pharmacological activities of Cinnamomum genus.

| Pharmacological activity | Cinnamomum plant/extracts/ fractions | Methods | Models cellular lines (in vitro)/animal (in vivo) | Effects/underlying mechanisms | Ref |
|--------------------------|--------------------------------------|---------|-----------------------------------------------|-------------------------------|-----|
| **Anti-cancer**          | **In vitro studies**                 |         |                                               |                               |     |
| C. burmanni stem bark/methanolic | NPC/ HK1, O666-1, human cancer cell lines |         | sixth toxicity                               | IC_{50} = 224.5 μg/ml       | Daker et al. (2013) |
| C. cassia bark aqueous   | SHa, human cervical carcinoma cell lines |         | growth of cancer cells                        | IC_{50} = 6.30 μg/ml        | Koppikar et al. (2010) |
| C. cassia ethanolic extract | HT 29, HCT 116, human colorectal cancer cell lines |         | antioxidant                                    | IC_{50} = 80 μg/ml          | Wondrak et al. (2010) |
| C. burmanni stem bark/aqueous | Lymphoma, melanoma, mice cancer cell lines |         | tumor cell growth                             | IC_{50} = 0.5 mg/ml         | Kwon et al. (2010) |
| Cinnamomum species       | HEP G2, hepatoma cells line          |         | apoptosis                                      | IC_{50} = 9.8 μM            | Ng and Wu. (2011) |
| C. subavenium miq subamolide D subamolide E | SW 480, human colon adenocarcinoma cell lines A431, SCC1 human epidermoid carcinoma cells A375, human melanoma cell lines |         | DNA damage                                     | IC_{50} = 9.12 μg/ml        | Kuo et al. (2008); Yang et al. (2013) |
| C. subavenium miq subamolide B, A | NTUB1, human uterine carcinoma cell line SW480, human colon adenocarcinoma cell line |         | tyrosinase                                     | IC_{50} = 13.30 μg/ml       | Chen et al. (2007); Wang et al. (2011) |
| C. terutilium/butanolides | DU145, human prostate cancer cell line |         | mitochondrial transmembrane potential         | IC_{50} = 17.59 μg/ml       | Lin et al. (2009) |
| **Neuroprotective**      | **In vitro studies**                 |         |                                               |                               |     |
| Cinnamomum species water extract/ procyanidin type a trimer | C6 glial cells, OGD exposed |         | glial cell swelling                            | IC_{50} = 50 μg/ml          | Panickar et al. (2012) |
| Cinnamomum cassia/extract/ cinnamaldehyde | BV2 microglia, LPS activated |         | glutamate uptake                               | IC_{50} = 5 μg/ml           | Ho et al. (2013) |
| **In vivo studies**      | Cinnamomum species trans-cinnamaldehyde | Mice/6-OHDA treated intracerebroventricular | Anti-neuroinflammatory | Dose = 30 mg/kg | Pyo et al. (2013) |
| Cinnamomum zeylanicum bark extract | Rats/SCOP treated intravenous |         | cognition dose = 100, 200, 400 mg/kg | IC_{50} = 1.03–2.1 μg/ml     | Jain et al. (2015) |
| **Others**               | **In vitro studies**                 |         |                                               |                               |     |
| Cinnamomum zeylanicum/stem bark/ methanol extract | Rats/L-NAME-induced hypertension, intravenous |         | Antihypertensive                              | Mosquitoidal                  | Nyadjeu et al. (2011) |
| Cinnamomum zeylanicum/bark and leaf/EDIs | Culex quinquefasciatus, Anopheles tesselatus and Aedes egypoti |         | Mosquitoidal                                  | C. unquiquefasciatus         | Samarakera et al. (2005) |
| Cinnamomum zeylanicum bark/EDs | Pediculus/humanus capitis |         | Ovocidal, adjuvactility                       | LD_{50} = 5 μg/cm²           | Yang et al. (2005) |
| Cinnamomum zeylanicum bark/ aqueous suspension | Rats |         | Anti-secretagogue                             | L-NAME                       | Aqiasouni. (2012) |
| Cinnamomum zeylanicum bark/ ethanol extract | Rats |         | Antilucre                                     | L-NAME                       | Kamarath et al. (2003); Farahpour and Habibi. (2012) |
| Cinnamomum zeylanicum bark/ ethanol extract | Rats |         | Pro-healing effect                            | L-NAME                       | Eid et al. (2012) |

Abbreviations and symbols: ↑, increase; ↓, decrease; APOA-1, Apolipoprotein A-1; bw, body weight; FBS, fasting blood glucose; L-NAME, L-NAME-nitro-L-arginine methyl ester; LPS, lipopolysaccharide; p53, tumor protein p53; PPG, postprandial plasma glucose; PTP1B, protein-tyrosine phosphatase; NF-κB, nuclear factor κB; OGD, oxygen-glucose deprivation; 6-OHDA, 6-hydroxydopamine; SCOP, scopolamine; STZ, streptozotocin; TBARS, thiobarbituric acid reactive substances.

Frontiers in Pharmacology | www.frontiersin.org  10  May 2021 | Volume 12 | Article 600139
The antidiabetic mechanisms of natural compounds derived from *Cinnamomum* spp. are explained as follows: 1) stimulation of insulin secretion by pancreatic β-cells of the islets of Langerhans, 2) increasing the muscle and hepatic glycogen content, 3) inhibition of α-amylase and α-glucosidase activities (key enzymes of carbohydrate metabolism) (Subash Babu et al., 2007; Zhang et al., 2008), 4) stimulation of glycogen synthesis and cellular glucose uptake by membrane translocation of glucose transporter (GLUT 4); stimulation of the glucose metabolism, 5) reduction of the gluconeogenesis by its actions on the most important regulatory enzymes, 6) potentiation of insulin release and increasing insulin receptor activity (Bandara et al., 2012; Ranasinghe et al., 2012). (Figure 3) and Table 2.

The antihyperglycemic action of the soluble polyphenols of *C. verum* bark was verified in SZT-induced diabetic rats at the dose of 200 mg/body weight (Krishnakumar et al., 2014). Cinnamaldehyde isolated from the volatile oil of *C. verum* showed a highly significant effect on plasma glucose levels using a rat model of SZT-induced diabetes (Subash Babu et al., 2007). This major component has a wide variety of pharmacological properties, including antihyperglycaemic activity in diabetic rats (Subash Babu et al., 2007; Zhang et al., 2008). Al-Logmani and Zari (2009) have also tested the EO of *C. verum* and showed an important reduction in blood sugar levels.

The chloroform extract of *C. verum* bark stem exhibited antidiabetic activity in vivo at 20 mg/body weight using a rat model of SZT-induced diabetes (Anand et al., 2010). The authors demonstrated that the chemical compounds of extract increased the muscle and liver glycogen content. By using alloxan-induced diabetes in rats, other studies showed that the EO of *C. verum* bark decreased fasting blood sugar in a dose-dependent manner and reduced total cholesterol level, blood urea, urinary protein, thiobarbituric acid reactive substances (TBARS), and catalase levels in diabetic rats (Rajbir et al., 2009; Mishra et al., 2010). A few studies have reported the antidiabetic effect of *C. verum* aqueous extracts (Verspohl et al., 2005; Kannappan et al., 2006; Ranilla et al., 2010; Shen et al., 2010; Chen et al., 2013).

The antihyperglycemic activity can also be evaluated by the inhibition test of α-glucosidase and α-amylase. Inhibitors of these enzymes are intended to maintain glucose homeostasis in diabetics by decreasing the rate of glucose uptake (Bösenberg and van Zyl, 2008; Hanhineva et al., 2010). (Ranilla et al., 2010) showed an important inhibition of α-glucosidase and α-amylase actions by *C. verum* bark aqueous extract. The same extract attenuated hyperglycemia depending on the dose in SZT diabetic rats (Shen et al., 2010; Chen et al., 2013). The antidiabetic effect of this extract was confirmed by the decrease in blood glucose using oral glucose tolerance test in rats (Kannappan et al., 2006; Chen et al., 2013).

In an *in vitro* study, *C. verum* showed a potential antidiabetic effect by reducing post-prandial intestinal glucose absorption via enzymatic reduction of pancreatic α-amylase and intestinal α-glucosidase. *In vivo* studies also confirmed the antihyperglycemic effects of *C. verum* (Bandara et al., 2012; Ranasinghe et al., 2012) through the decrease in LDL cholesterol, total cholesterol and triglycerides with increasing HDL in hyper-lipidaemic albino rabbits (Javed et al., 2012).
Antioxidant Activity

Some clinical investigations showed that long term consumption of cinnamon extracts improved the levels of blood markers of oxidative stress, such as the antioxidant capacity. The extracts also reduced the transaminase and lipid peroxidase activities (Ranjbar et al., 2007; Rashidi et al., 2014). Diverse tests were used to evaluate potential antioxidant action of *Cinnamomum* plant extracts and secondary metabolites. These include 2,2′-azinobis (3-ethyl-benzothiazoline-6-sulphonic acid (ABTS), 2,2′-diphenyl-1-picrylhydrazyl (DPPH), ferric reducing antioxidant power (FRAP), oxygen radical absorbance capacity (ORAC), Folin Ciocalteu reduction assay (FCR), β carotene linoleic acid bleaching (BCLB), and enzyme inhibition assays.

The antioxidant activity of *C. osmophloeum* leaf EOs was assessed using DPPH radical scavenging assay, with IC₅₀ = 29.7 μg/ml (Lin et al., 2007). The ethanol extract of the same species was tested using DPPH and FRAP assays by (Lee et al., 2015). The results showed inhibitory values of 38.97 and 0.48% by DPPH and FRAP test, respectively.

(Prasad et al., 2009) tested the antioxidant activity of ethanolic extract of *Cinnamomum curvifolium* (Lam.) Nees, *C. burmanni, C. cassia, C. verum*, and *C. tamala* using DPPH, FRAP and ORAC assays. All tested species showed important antioxidant activities with some variability depending on the species and the used method (Prasad et al., 2009). *C. cassia* was also reported as an antioxidant species by several studies (Lin et al., 2003; Kim et al., 2006; Jang et al., 2007). *C. cassia* water extract showed important capacities to inhibit the key enzymes involved in ROS generation such as catalase, superoxide dismutase and glutathione peroxidase (Kim et al., 2006). Methanolic extract of *C. verum* revealed remarkable antioxidant activities particularly by chelating metal and inhibition of lipid peroxidation (Mathew and Abraham, 2006). Moreover, the inhibition of lipid peroxidation was also demonstrated by EOs of *C. verum* (Jayaprakasha et al., 2003; Jayaprakasha et al., 2006). The research that highlighted the antioxidative activity of *Cinnamomum* plants is summarized in Table 2.

### Anti-inflammatory Activities

Inflammation is an important pathophysiological process of the organism that maintains homeostasis, fighting pathogens and repairing damaged tissues caused by various injuries such as trauma, infection or immune response (Salehi et al., 2019b), (Stalnikowitz and Weissbrod, 2003). The same inflammatory process is involved in the maintenance of several disorders and is characterized by the production of diverse pro-inflammatory mediators (Salehi et al., 2020a). The current common class of medications against inflammation disorders still relies on non-steroidal anti-inflammatory drugs (Padureanu et al., 2019). However, in spite of having important anti-inflammatory potential, these drug class can cause several side effects such as bleeding, kidney failure and gastrointestinal ulceration. Therefore, increasing attention has been directed towards natural and health-friendly alternatives (Salehi et al., 2019c; Salehi et al., 2019d). The use of natural compounds constitutes an attractive approach for the treatment of several inflammatory disorders.

Inflammation involves reactive oxygen species (ROS) generation, NO production, phospholipase A₂ activation and histamine release in neutrophils, macrophages and mast cells. NO has an important role in lipopolysaccharide (LPS), TNF or IL-1 mediated inflammatory process. It is also essential in the cell function maintenance (Stalnikowitz and Weissbrod, 2003) though, on the other hand, NO is able to induce cell injury as a reactive radical. The activator protein-1 (AP-1) and nuclear factor kappa B (NF-kB) are important modulators of inflammation.

The main mechanism of the anti-inflammatory activity of the major chemical compound of *Cinnamomum* plants, cinnamaldehyde is the effective inhibitor of the expression of NF-kB mediated by its antioxidant activity (Kim et al., 2007). In addition, cinnamaldehyde inhibits pro-inflammatory mediators such as chemokines, interferons, interleukins, lymphokines, eicosanoids (prostaglandins and leukotrienes) and ROS involved in Alzheimer’s disease (Latta et al., 2015). Preclinical
studies showed a reasonably good anti-inflammatory effect of *Cinnamomum* constituents. Diverse extracts and isolated compounds of *Cinnamomum* plants have been studied for possible anti-inflammatory activity in various animal models. (Liao et al., 2012b) showed an anti-inflammatory effect of cinnamaldehyde on lipopolysaccharide (LPS) stimulated mouse macrophage (RAW 264.7) at 50 µM.

The *in vivo* investigations confirmed the anti-inflammatory effect using the carrageenan-induced mouse paw edema (Liao et al., 2012b). Cinnamic alcohol (another volatile compound from *Cinnamomum* plants) also exerted anti-inflammatory activity using the same model (Liao et al., 2012b). In another study, cinnamyl acetate revealed a significant anti-inflammatory action on LPS-stimulated mouse macrophages (RAW264.7) (Chua et al., 2008). The research highlighting the anti-inflammatory activity of *Cinnamomum* plants is displayed in Table 2.

### Anticancer Activities

Recent researches showed that the *in vivo* anticancer activity of the cinnamom extract was mediated by the induction of tumor apoptosis through the inhibition of NF-κB levels (Kwon et al., 2010). On the other hand, cinnamon showed important anticancer effects via affecting on numerous cancer-related pathways such as apoptosis (Kwon et al., 2010). This apoptotic action is mediated by targeting Fas/Fas/CD95, caspase-3, and Bcl-XL (B-cell lymphoma-extra-large) pathways (Sadeghi et al., 2019).

C. burmanni stem bark methanolic extract was tested on human cell lines (NPC/HK1 and C666-1) by Daker et al. (2013). The results showed important cytotoxic effect against HK1 (IC50 = 224.3 µg/ml) and C666-1 (IC50 = 6.30 µg/ml) Daker et al. (2013). Koppikar et al. (2010) tested the aqueous bark extract of C. cassia on human cervical carcinoma (SiHa) cell lines. This extract decreased the growth of cancer up to 2-fold compared to the untreated control cells at the concentration of 80 µg/ml Koppikar et al. (2010).

In another study, the ethanolic extract of the same species tested by Wondrak et al. (2010) on human colorectal carcinoma (HCT 116 and HT 29) cell lines showed anticancer properties. The C. cassia bark aqueous extract was evaluated on cancer cell lines of lymphoma, melanoma and cervix as well as in a melanoma mouse model (Kwon et al., 2010). The cinnamon extract inhibited tumor cell growth *in vitro* at 0.5 mg/ml.

Cinnamaldehyde showed an important antitumor effect as well (Ng and Wu, 2011). It inhibited the growth of hepatoma Hep G2 cells line at IC50 = 9.8 µM. Some bioactive compounds isolated from *Cinnamomum subveniens* Miq, such as subamolide D and E showed remarkable anticancer effects on human colon adenocarcinoma (SW 480) cell lines. The cytotoxic effect was mediated by the capacity of these compounds to cause DNA damage in a dose- and time-dependent manner (Kuo et al., 2008). Moreover, subamolide B isolated from the stem of the same plant showed significant cytotoxic effects on human SCC12 (IC50 = 9.12 µg/ml), epithoid carcinoma A431 (IC50 = 13.30 µg/ml), and human melanoma A375 (IC50 = 17.59 µg/ml) cell lines (Yang et al., 2013).

In another study, subamolide B and its isomer subamolide A induced apoptosis in human colon adenocarcinoma cell line SW480 and human urothelial carcinoma cell line NTUB1 (Chen et al., 2007; Wang et al., 2011). Furthermore, subamolide E, isolated from *C. subveniens*, exhibited an important *in vitro* anti-melanoma activity (Kuo et al., 2008; Wang et al., 2011). (Lin et al., 2009) reported that butanolides isolated from the stem of *Cinnamomum tenuifolium* (Makino) Sugim showed anticancer activity on human prostate cancer (DU145) cell line. (Lin et al., 2009). In addition, the extracts of *C. kotoense* was found cytotoxic against HeLa cells (Chen et al., 2008).

Butanolides isolated from the *C. kotoense* leaves reported genotoxic and cytotoxic effects on various cell lines, such as human laryngeal carcinoma cells Hep-2, Chinese hamster ovarian cells CHO-K1 and rat hepatoma tissue cultures (Garcez et al., 2005) and mouse lymphoid leukemia P-388 cells (Tsai et al., 2002). *In vitro* antineoplastic activities of *Cinnamomum* species are summarized in Table 2.

### Neuroprotective Activities: Potential Mechanisms and Molecular Targets in Neurodegenerative Diseases

Parkinson’s and Alzheimer’s diseases are common neurodegenerative diseases, accompanied by cognitive and memory impairments, sometimes difficult to differentiate from real psychosis or other neurological diseases (Nussbaum et al., 2017; Buga et al., 2019; Tsatsakis et al., 2019). The mechanisms of neuroprotective effects of *Cinnamomum* plants and their derivatives have been reported by several studies (Liao et al., 2008; Peng et al., 2008; Peterson et al., 2009; Panickar et al., 2012; Jiao et al., 2013). (Figure 4).

(Ho et al., 2013) showed that procyanidinA trimer 1 (a bioactive compound isolated from *C. burmanni*) had an essential neuroprotective effect which reduced the glial swelling by regulating the intracellular calcium concentration in glial neuronal cells (Peng et al., 2008). Procyanidin exhibited neuroprotective activity by its capacity to regulate the secretion of S100 via the regulation of SIRT1 and the suppression of TNF-γ, NF-kB p65 (RelA subunit of NF-kB family of transcription factors) and B-cell lymphoma 2 (Bcl-2) on glioma cells (Jiao et al., 2013).

(Panickar et al., 2012) studied the neuroprotection of procyanidin B2 isolated from *C. verum*. The results showed that this molecule inhibited advanced glycation end-product production in the bovine serum albumin-glucose model (Panickar et al., 2012).

Cinnamaldehyde is a volatile compound found in *C. cassia* extracts. (Ho et al., 2013) showed that this compound possessed an important neuroprotective effect by reducing the expression of NO, tumor necrosis factor (NF-γ), interleukin-1beta (IL-1b), interleukin 6 (IL-6), and nuclear factor-kappa B (NF-kB) in LPS induced BV2 microglia cells.

In a recent study, (Liao et al., 2008) revealed that cinnamaldehyde from *C. cassia* exhibited remarkable neuroprotection by the reduction of TNFγ-induced expression of cell adhesion molecules, the suppression of nuclear factor-kappa B (NF-kB) and the reduction of intracellular thiols in endothelial cells (Liao et al., 2008).

Cinnamaldehyde isolated from *C. ramulus* exhibited anti-neuro-inflammatory properties by the inhibition of inducible
### TABLE 3 | Description of recent clinical studies related to pharmacological activity of natural compounds from Cinnamomum species.

| Pharmacological activity | Clinical trial/study design (type, patients included) | Period, country | Intervention (doses of Cinnamom and its derivatives) | Standard comparison | The most representative clinical outcomes | Ref |
|--------------------------|---------------------------------|-----------------|--------------------------------------------------|---------------------|------------------------------------------|-----|
| Type 2 diabetes          | Two groups included: Cinnamon-group 1, 2, 3, Placebo-group 4, 5, 6, Cinnamon group: 60 patients Age 52.2 ± 6.32 years Not on insulin therapy Not taking other medicine Fasting blood glucose Levels 7.8–22.2 mmol/L | Department of Human Nutrition, NWFP Agricultural University, Peshawar, Pakistan | Cinnamon group: 500 mg capsule of Cinnamomum cassia placebo group: Wheat flour, 500 mg, 1 g or 2 capsules per day for 20 days; group 1 and 4: 3 g or 6 capsules per day for 20 days; group 2 and 5: 6 g or 12 capsules per day for 20 days; group 3 and 6: 6 g or 12 capsules per day for 40 days | Placebo | ↓ serum glucose (18–29%), ↓ TG (23–30%), ↓ LDL-C (7–27%), ↓ total cholesterol (12–26%) | Khan et al. (2003) |
| Type 2 diabetes          | Cinnamon group: 33 patients, age 62.8 ± 8.37 Body weight 88.5 ± 19.1 kg HbA1c 6.7–6.9% Placebo group: 32 patients age 63.7 ± 7.17 years Body weight 89.9 ± 14.1 kg HbA1c 6.7–6.9% | Hannover, Germany | Cinnamon group: Extract 112 mg aqueous cinnamon extract placebo: Microcrystalline cellulose 3 g powder per day, three times a day for 4 months | Placebo | ↓ glucose levels up to 10.3% | Mang et al. (2006) |
| Type 2 diabetes          | Cinnamon group: 12 postmenopausal women age 62 ± 2 years Body weight 85.4 ± 3.6 kg Placebo group: 13 patients Age 64 ± 2 years Body weight 82.2 ± 4.0 kg HbA1c 6.7–6.9% | Netherlands | Cinnamon group: 500 mg of Cinnamomum cassia placebo group: 500 mg, wheat flour, verstegen 1.5 g per day, 1 capsule at breakfast, lunch and dinner for 6 weeks | Placebo | ↓ plasma glucose, ↓ plasma insulin, ↓ total cholesterol, ↓ LDL, ↓ TG, ↓ HDL, ↓ HbA1c | Vanschoonbeek et al. (2006) |
| Type 2 diabetes          | Cinnamon group: 30 patients Age 63.6 years Placebo: 22 patients Age 58.0 years | US | Cinnamon group: 500 mg capsule of Cinnamomum cassia placebo group: Wheat flour, 500 mg capsule: 1 g per day, for breakfast and dinner for 3 months | Placebo | No significant change in FBG, lipid for cinnamon group | Blevins et al. (2007) |
| Type 2 diabetes          | Cinnamon group: 55 patients Age 60.5 ± 10.7 HbA1c ≥ 7.0% control group: 54 patients Age 59.9 ± 9.2 years HbA1c ≥ 7.0% | United States military base, May 2007 to August 2007 | Cinnamon group: Capsules 500 mg capsule of Cinnamomum cassia control group: 1 g/day with food for 90 days | Control | Cinnamon group ↓ HbA1c | Crawford. (2009) |
| Multi-ethnic type 2 diabetic | Cinnamon group: 58 patients, age 54.9 ± 9.8 years Body weight 74.9 ± 13.34; FPG≥ 7 mmol/L HbA1c ≥ 7.0% placebo group: 22 patients Age 55.67 ± 7.98 years Body weight 73.02 ± 10.38 years FPG≥7 mmol/L HbA1c ≥ 7.0% | October 2007 to January 2009, United Kingdom | Cinnamon group: 500 mg capsule of Cinnamomum cassia placebo: Starch, 500 mg capsule 2 g per day, for breakfast (1 capsule), lunch (2 capsules), dinner (1 capsule) for 12 weeks | Placebo | ↓ HbA1c, ↓ FPG, ↓ BMI | Akilen et al. (2010) |

(Continued on following page)
| Pharmacological activity | Clinical trial/study design (type, patients included) | Period, country | Intervention (doses of *Cinnamon* and its derivatives) | Standard comparison | The most representative clinical outcomes | Ref |
|--------------------------|-------------------------------------------------------|-----------------|------------------------------------------------------|--------------------|----------------------------------------|-----|
| Type 2 diabetes          | Cinnamon group: 22 patients Age 54.1 ± 10.37 years Body weight 74.9 ± 13.34 | Tehran, Iran | Cinnamon group: 500 mg capsule of *Cinnamomum zeylanicum* placebo group: 500 mg capsule, wheat flour 3 g per day, 2 capsules at breakfast, lunch and dinner for 8 weeks | Placebo | No significant difference in cinnamon and placebo group on HbA1c, ↓TG, ↓Insulin ↑LDL-C | Vafa et al. (2012) |
| Type 2 diabetes          | Cinnamon group: 137 patients Age 61.3 ± 0.8 years | Beijing and dalian, China | Cinnamon group: Water extract of cinnamon and CinSulin®, 250 mg/capsule placebo: 500 mg capsule, wheat flour daily, twice a day for 2 months | Placebo | ↓LDL-C ↓HDL ↓HOMA-IR | Anderson et al. (2015) |
| Type 2 diabetes          | Cross-over study cinnamon group: 10 sedentary obese females Age 22.7 ± 4 years Body weight 104.4 ± 16.75 kg Take oral/intrauterine contraceptives Prescription medications Over-the-counter weight loss pills | Texas, United States | Cinnamon group: 1–6 g/day powder of *C. cassia* /*aromaticum* and *C. zeylanicum* /*verum* placebo: Cellulose powder 5 g | Placebo | No differences observed in blood glucose, serum insulin, insulin sensitivity, insulin resistance | Gutierrez et al. (2016) |
| Type 2 diabetes          | Cinnamon group: 40 patients Age 54.15 ± 1.0 years Weight 75.62 ± 1.2 kg Control group: 40 patients Age 53.84 ± 1.3 years Weight 78.74 ± 1.2 kg | September 2012 to December 2012, Iran | Cinnamon group: *Cinnamomum verum* 3 g for 8 weeks control group: 3 glasses of tea, for 8 weeks | Control | ↓sICAM-1 | Azimi et al. (2016) |
| Polycystic ovary syndrome | Herbal medicine plus lifestyle intervention study Cinnamon group: 60 overweight women Age 29.2 ± 5.6 years Weight 93.2 ± 18.9 kg Lifestyle intervention group: 62 patients age 28.9 ± 5.6 Weight 97.3 ± 21.3 kg | August 2012 to January 2014, Australia | *Glycyrrhiza glabra, Paeonia lactiflora, Cinnamomum verum, Hypericum perforatum*: three tablet per day for 3 months | Lifestyle intervention | ↓oligomenorrhoea ↓BMI ↓weight | Arentz et al. (2017) |
| Polycystic ovary syndrome | Cinnamon group: 29 patients Age 18–45 years Weight 68.2 ± 9.68 kg Placebo group: 30 patients Age 18–45 years 63.26 ± 11.62 kg | Iran | Cinnamon group: 500 mg capsules (450 mg capsule of starch and 50 mg cinnamon powder); 1.5 g per day three times, after a meal with 10 mg medroxyprogesterone tablet from 15th day of menstruation cycle for 10 days for 12 weeks | Placebo | ↓fasting insulin, ↓HOMA-IR, ↓LDL, ↓TG, ↓testosterone, ↓insulin, ↓weight ↓HbA1c | Hajmonfarednejad et al. (2018a) |

(Continued on following page)
TABLE 3 | (Continued) Description of recent clinical studies related to pharmacological activity of natural compounds from Cinnamomum species.

| Pharmacological activity       | Clinical trial/study design (type, patients included) | Period, country                           | Intervention (doses of Cinnamomum and its derivatives) | Standard comparison | The most representative clinical outcomes | Ref                        |
|-------------------------------|-------------------------------------------------------|-------------------------------------------|------------------------------------------------------|---------------------|----------------------------------------|--------------------------|
| Polycystic ovary syndrome     | Cinnamon group: 42 patients with rotterdam criteria  | September 2015 to January 2016, Tehran, Iran | Cinnamon group: 500 mg capsule/day placebo: Wheat flour: 1.5 g per day for 8 weeks | Placebo             | [antioxidant capacity, malondialdehyde] | Borzoei et al. (2018a) |
| Polycystic ovary syndrome     | Cinnamon group: 42 patients with rotterdam criteria  | Mohheb Yas Hospital, Tehran, Iran, October 2015 to February 2016 | Cinnamon group: 500 mg capsule/day placebo: Wheat flour: 1.5 g per day for 8 weeks | Placebo             | [TG, LBM, TC, HOMA-IR, insulin, HDL-C, LDL-C] | Borzoei et al. (2018b) |
| Polycystic ovarian syndrome   | Cinnamon group: 11 patients, age 18–38 years with oligomenorrhea or amenorrhea | March 2011 to April 2014, United States | Cinnamon (125 mg capsule) or placebo: 1.5 gm per day for 6 months | Placebo             | ↑ homa-ir                              | Kort and Lobo. (2014a) |
| Polycystic ovarian syndrome   | DLBS3233: 18 patients Metformin group: 22 patients  | March 2013 and June 2015 at yasmin clinic, RSOM kencana, jakarta and hasan sadikin hospital, bandung, Indonesia | DLBS3233 (Cinnamomum burmanii and Lagerstroemia speciosa): 200 mg per day for 6 months metformin group: 1.5 g per day for 6 months | Control             | [AMH level]                            | Wiweko and Susanto. (2017) |
| Polycystic ovarian syndrome   | Patients age 23.29 ± 5.10 with rotterdam, overweight or obese | March 2017, Ahvaz, Iran | Cinnamon extract (323 mg/day) | Placebo             | [BMI]                                 | Talaat and Ammar, (2018) |
| Polycystic ovary syndrome     | 40 patients age 18–30 years                          | December 2014 to March 2016, national institute of unani medicine (NIUM) hospital, Bengaluru | Cinnamon group: 750 mg capsule, 1.5 g/day control group: 500 mg metformin twice a day for 60 days | Intervention group Control | [weight glucose homeostasis no effects, menstrual cycle improvement increased 51.9%, insulin resistance unchanged] | Parseh et al. (2019) |
| Polycystic ovary syndrome     | Cinnamon group: 20 patients, age 18–42 years with RouterModule criteria | 2017, Ahvaz, Iran | 6 weeks | Intervention group Control |                                    | Khan and Begum. (2019) |

Other Pharmacological Activities

Cinnamomum plants have also shown an array of other biological activities. (Nyadjeu et al., 2011) reported that C. verum extracts decreased arterial blood pressure in rats with normal arterial hypertension and various models of hypertensive rats (salt-loaded and spontaneously) (Nyadjeu et al., 2011). In another study, (Wansi et al., 2007) reported that C. verum extracts showed similar effects in arterial blood pressure of normotensive rats and salt-loaded hypertensive rats. Moreover, they showed that C. verum had a vasorelaxant action on the thoracic aortic ring segments, which suggests that C. verum might inhibit nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) in LPS-induced BV2 microglial cells (Pyo et al., 2013).

In addition, cinnamon bioactive compounds exhibited neuroprotective effects in in vivo models of Alzheimer’s disease and extended the lifespan via regulation of key antioxidant pathways (Crews et al., 2016). C. verum extracts provided an important protection against Alzheimer’s disease and dementia in the scopolamine-induced memory impairment in experimental rat model (Jain et al., 2015).

In the same way, a different mixture of cinnamon rich in polyphenols exhibited important neuroprotective activities in rat glioma cells by suppression of pro-inflammatory cytokines, upregulation of sirtuin 1 (SIRT1) and activation of mitogen-activated protein kinase (MAPK) pathways (Qin et al., 2014). Neuroprotective activities of Cinnamomum plants are tabulated in Table 2.
extracellular calcium through L-type voltage-sensitive channels (Wansi et al., 2007).

The antiparasitic effects of EOs from bark and leaves of *C. verum* were investigated by (Samarasekera et al., 2005) against *Anopheles tessellates, Culex quinquefasciatus*, and *Aedes aegypti*. These oils showed knock-down and mortality against *A. tessellatus* (LD₅₀ = 0.33 μg/ml) and *C. quinquefasciatus* (LD₅₀ = 0.66 μg/ml). (Yang et al., 2005) observed fewer effect of *C. verum* bark EO against *Pediculus humanus capitis* (eggs, adult females of human head louse) than either permethrin or pyrethrum using direct contact bioassay (Yang et al., 2005).

Collagen synthesis was stimulated in human dermal fibroblasts by *C. verum* extracts (Takaso et al., 2012). *C. verum* extract enhanced both mRNA and protein expression levels of type I collagen without cytotoxicity, and cinnamaldehyde was the most active component stimulating the expression of collagen, suggesting that *C. verum* extracts might be useful in skin anti-aging treatments (Takaso et al., 2012). Moreover, *C. verum* extracts inhibited osteoclastogenesis (Tsuji-Naito, 2008). At concentrations of 12.5–50 μg/ml, *C. verum* inhibited osteoclast-like cell formation in a dose-dependent manner without affecting cell viability. This finding suggests its potential use in the treatment of osteopenia diseases (Tsuji-Naito, 2008). In addition, *C. verum* exhibited *in vivo* anti-secretagogue and anti-gastric ulcer effects (Alqasoumi, 2012). In pylorus-ligated rats, *C. verum* extract pre-treatment reduced the basal gastric acid secretion and inhibited gastric hemorrhagic lesions (Alqasoumi, 2012). Furthermore, *C. verum* extracts at 100 and 200 mg/b. w. effectively diminished the extent of diarrhea (71.7 and 80.4%, respectively) in test animals (RAO, 2012).

In another research performed in two rat models, the evaluation of anti-nociceptive effects of *C. verum* and selected plants showed that *C. verum* produced a dose-dependent analgesic protective effect against thermal stimuli. Moreover, *C. verum* enhanced an anti-inflammatory activity against chronic inflammation of cotton pellet granuloma (Atta and Alkofahi, 1998; RAO, 2012). *C. verum* has also demonstrated wound healing properties (Kamath et al., 2003; Farahpour and Habibi, 2012). *C. verum* (0.01, 0.05, and 0.1 g/b. w. for 28 days) displayed hepatoprotective effects in a study where the liver injury was induced in rats by CCl₄ (carbon tetrachloride) (Eidi et al., 2012). Other pharmacological properties of *Cinnamomum* plants are summarized in Table 2.

**CLINICAL TRIALS RELATED TO EFFICACY OF BIOACTIVE COMPOUNDS DERIVED FROM CINNAMOMUM**

**Type 2 Diabetes Mellitus, Obesity and Metabolic Syndrome**

Cinnamon consumption was associated with reduction in the levels of fasting plasma glucose (FPG), total cholesterol (TC), triglyceride levels (TG), LDL cholesterol and hemoglobin A₁c (HbA₁c). In one study, cinnamon consumption resulted in significantly increased FPG levels and HbA₁c (Blevins et al., 2007) or no significant change in HDL cholesterol levels. However, the most preferred and effective doses with fewer side effects are still not clear. Doses applied in randomized clinical trials showed conflicting results as consumption of 1 g/day (Khan et al., 2003; Blevins et al., 2007; Crawford, 2009), 1.5 g/day (Vanschoonbeek et al., 2006; Radhia et al., 2010), 2 g/day (Akilen et al., 2010), 3 g/day (Khan et al., 2003; Mang et al., 2006; Vafa et al., 2012), or 5 g/day (Gutierrez et al., 2016), 6 g/day (Khan et al., 2003) showed different effects in glycemic and lipid parameters. FPG and HbA₁c are commonly used parameters for diabetes diagnosis. HbA₁c values of more than 6.5% can be related to diabetes. Vafa et al. showed FPG and HbA₁c at baseline modestly elevated (7.02 mmol/L to 8 mmol/L) and 6.9–8.0%, respectively (Vafa et al., 2012). Both the studies by Akilen et al. and Crawford reported a drop of 0.36 and 0.83% of HbA₁c values at low dose cinnamon supplementation which were safe and well tolerated for 3 months in patients using simultaneous hypoglycemic medications (Crawford, 2009; Akilen et al., 2010). Mang et al. observed that aqueous extract of cassia cinnamon significantly reduced glucose levels like 10.3% in the cinnamon group and 3.4% in the placebo group, however, no considerable difference in HbA₁c and cholesterol (LDL, HDL, TC) levels were observed (Mang et al., 2006). Suppapitiporn et al. observed no significant differences in cinnamon and placebo group for FPG and lipid profiles but HbA₁c level decreased in both groups by 0.38 and 0.19% respectively (Suppapitiporn and Kanpaks, 2006).

Khan et al. reported that intake of 1, 3, or 6 g of cinnamon reduced fasting serum glucose by 18–29%, LDL by 7–27%, triacylglycerol by 23–30%, and total cholesterol by 12 26% after 40 days treatment. Nevertheless, they did not investigate the HbA₁c value (Khan et al., 2003). One study showed that, consumption of *Cinnamomum cassia* powder 1.5 g/day for 6 weeks, did not improve plasma glucose levels, insulin, and cholesterol levels and no reduction in HbA₁c level was noted (Vanschoonbeek et al., 2006). Only one trial by Blevins et al. observed significant increases in HbA₁c and FPG levels (Blevins et al., 2007). In healthy, sedentary and obese women with increased in serum associated with increasing type-2 diabetes. Vafa et al. showed significant increase in serum ICAM-1 level in patients with type-2 diabetes (Azimi et al. studied that consumption of *Cinnamomum verum* extract for 8 weeks decreased serum ICAM-1 level in patients with type-2 diabetes (Azimi et al., 2016).

26 clinical trial studies on cinnamon are present on Clinical Trials Govt. Database, among them most of the studies are under process and 14 studies are completed. Clinical trial numbers NCT03219411 and NCT01301521 showed effects of cinnamon supplementation in pre-diabetic patients. Clinical trials...
NCT03711682 and NCT00237640 observed plasma glucose and lipid levels reduction mediated by cinnamon in type 2 diabetic patients and in non-insulin dependent type 2 diabetes mellitus patients respectively. NCT01302743 trial demonstrated the application of water-soluble cinnamon bark extract and metformin for the treatment of type 2 diabetes mellitus patients. Table 3 displayed the clinical studies on Cinnamon plants in relation to diabetes.

Neurodegenerative Disorders

Neurodegenerative disorders (ND) include disorders like Alzheimer’s disease, amyotrophic lateral sclerosis, Parkinson’s disease, Huntington’s disease, motor neuron disorder, and frontotemporal dementia that result from slow progressive and unalterable drop of certain areas of the nervous system, leading to disruption in nervous system working or death (Nussbaum et al., 2017).

Various Cinnamomum species displayed efficacy in the management of neurodegenerative diseases. Several in vitro studies are present for cinnamon that can regulate factors that trigger neurodegenerative diseases. Cinnamon extract inhibited Tau aggregation in vitro attenuating Alzheimer’s diseases (Peterson et al., 2009). C. cassia bark extracted in ethanol demonstrated in vitro efficacy against Huntington disease Kaur and Shri (2018). Therefore, cinnamon is necessary to put into clinical trials that develop drugs for neurodegenerative disorders. One clinical trial (NCT03225144) for patients with motor neuron disorder, frontotemporal dementia, or related adult-onset neurodegenerative disorder is ongoing involving 200 participants (Table 3).

Polycystic Ovary Syndrome: A Possible Control on Its Metabolic Parameters

Polycystic ovary syndrome (PCOS) is caused by an associated endocrine dysfunction and is associated with increased risk of developing insulin resistance, type 2 diabetes, high blood pressure, hypercholesterolemia and heart disease.

Several clinical trials reported conflicts in results for cinnamon efficiency on the improvement of BMI, body weight, oxidative stress, and fertility (Hajimonfarednejad et al., 2018a; Borzoei et al., 2018b; Khan and Begum, 2019). Consumption of daily 1.5 g cinnamon did not show any significant effect on BMI and body weight but improved glucose balance in patients with PCOS (Hajimonfarednejad et al., 2018a). However, Borzoei et al. decreased BMI and improved glucose balance treated with the same concentration as applied by Hajimonfarednejad et al. (Hajimonfarednejad et al., 2018a; Borzoei et al., 2018b). Oral supplementation of cinnamon also showed weight loss. This study further exhibited decreased BMI in comparison to the placebo group in PCOS patients (Talaat and Ammar, 2018; Parseh et al., 2019). In contrast to the report by Hajimonfarednejad et al. and Kort and Lobo observed that oral cinnamon consumption did not show any effect on serum glucose balance in PCOS patients (Kort and Lobo, 2014a; Hajimonfarednejad et al., 2018a). This study also supported by Parseh et al., who also did not report any changes in glucose homeostasis (Parseh et al., 2019). All of the studies discussed here showed an effective dose of cinnamon as 1.5 g per day, three times after meal for 1.5–6 months except Talaat and Ammar reported effective dose of 336 mg cinnamon extract per day whereas Wiweko and Susanto (2017) treated with 200 mg of Cinnamomum burmanii and Lagerstroemia speciosa combination extract (Talaat and Ammar, 2018).

Serum LDL-C, TG and TC levels were also found to be improved in PCOS patients in comparison to placebo (Hajimonfarednejad et al., 2018a; Borzoei et al., 2018b). However, HDL-C level did not show any significant improvement (Borzoei et al., 2018b). Khan and Begum observed no changes in insulin resistance and did not found any significant improvement in patients’ life in comparison with metformin treatment as a control (Khan and Begum, 2019).

Herbal medicine combination extract of Glycyrrhiza glabra, Paeonia lactiflora, Cinnamomum verum and Hypericum perforatum (supplemented with 1.5 g tablet per day for 3 months) with lifestyle intervention positively improved menstrual regulation and reduction in oligomenorrhea of 32.9% in patients in comparison with only lifestyle intervention in overweight women with PCOS (Arentz et al., 2017).

Oxidative stress is one of the main causes for increasing lipogenes, BMI in PCOS due to molecular damage, and reduction of serum antioxidants. Borzoei et al. demonstrated that cinnamon extract has antioxidant activity that can improve oxidative stress in women with PCOS (Borzoei et al., 2018a).

Table 3 summarized the clinical studies on cinnamon plants in relation to PCOS.

TOXICOLOGICAL SAFETY AND ADVERSE EFFECTS OF NATURAL DERIVATIVES OF CINNAMOMUM SPECIES

Besides the numerous health benefits, all phyto-therapeutics are not always safe and might result in adverse effects such as allergic dermatitis, the toxicity of organs and interactions with foods and pharmaceuticals (Calixto, 2000). The usual dose for dietary supplements has been suggested to be between 1 and 4 g per day (NIHU, 2015). The usual doses for the administration of cinnamon oil, which is stronger, vary between 50 and 200 mg per day. For doses up to 6 g per day, no adverse reactions were reported (Yun et al., 2018). The common use of cinnamon in food as a spice, food additives and flavoring agent would suggest that it is likely to be safe (Gowder, 2014). However, when consumed in excess, cinnamon can cause respiratory distress, increase pulse rate and increase the sweating process, followed by depressive and drowsy states. This may aggravate the symptoms of rosacea and may increase the risk of developing oral cancer. Coumarin, naturally found in cinnamon, can have a negative influence on the liver, so people with liver disorders should avoid excessive consumption (Organization, 2001).

Cinnamon extract at different doses didn’t produce any toxicity or mortality on rats, as well as no adverse effect was observed (Ahmad et al., 2013) though trans-cinnamaldehyde and coumarins are toxic components of cinnamon (Woehrlin et al., 2010; Zhang
et al., 2010). High levels of coumarin and cinnamaldehyde might be correlated to liver damage (Deng, 2012), risk of cancer (Abraham et al., 2010), mouth sores (Vivas and Migliari, 2015), low blood sugar (Disakwattana et al., 2011; Deng, 2012) breathing problems and interaction with certain medications (Abraham et al., 2010). Therefore, the long-term use of a high amount of cinnamon should be continuously monitored. The tolerable daily intake for coumarin (0.1 mg/b. w.) is to be regarded as safe in terms of daily cinnamon intake without the risk of adverse effects (Abraham et al., 2010). When used in large quantities Cinnamomum may interact with certain drugs, which could damage the liver.

Used externally, the cinnamon essential oil can produce skin redness, irritation and burning sensation in the epidermis (Markman, 2002). In addition, negative interactions with the drugs such as statins, acetaminophen, amiodarone (used to treat heart conditions), carbamazepine (given in the treatment of seizures), medicines for treating fungal infections, methotrexate (used in antitumor treatments) and methyldopa (used in hypertension) may also occur.

Because cinnamon can reduce the concentration of blood sugar, consumed in large quantities, it can interact with diabetes medicines, leading to a very low level of sugar. It is also possible to interfere negatively with tetracycline. Noteworthy, the safety of cinnamon is dependent on supplier quality assurance (SQA), good manufacturing practice (GMP) and good agricultural practice (GAP). It is necessary to control the cultivation, harvesting, plant identification, contamination, adulteration, preparation, packaging, transportation, storage etc. In order to guarantee the safety of the cinnamon products, it is required to assess the quality control of identity/authenticity and purity, stability and shelf life, toxicity physical/chemical/biological/ microbial properties and finally standardization of the plant material as well as the products (Kumari and Kotecha, 2016).

**DISCUSSION**

One of the strengths of this updated review is that the pharmacological effects highlighted in preclinical in vitro studies and in vitro models could be translated into recent clinical trials in human subjects at well-defined doses, providing strong scientific evidence-based support for therapeutic effects. ethnopharmacological features of cinnamomum species.

In addition, current toxicological data show that unwanted side effects may occur at higher doses of cinnamon than shown in pharmacological studies.

Another strength of this comprehensive review is the summarized presentation of the pharmacological mechanisms and molecular targets of action resulting from the meta-analyses included in the study in order to open new clinical pharmacotherapeutic perspectives.

Starting from traditional uses, pharmacognostic research on Cinnamomum plants have identified chemical compounds with biological activities. Three major components found in cinnamon oil and powder: are cinnamaldehyde, acetate, and cinnamyl alcohol, give it beneficial properties. Also, cinnamon is a good source of iron, calcium, manganese and dietary fiber (Vallverdú-Queralt et al., 2014).

Plant organic extracts are a rich source of antimicrobial agents and methanol extracts are known for their antimicrobial properties. Indeed, organic solvents have a good ability to solubilize the active components (de Boer et al., 2005) and their use does not influence the bioactivity of these components (Goyal et al., 2009). (Thongson et al., 2004) also suggested that organic solvents are better solvents of antimicrobial substances. Therefore, a number of preclinical experimental studies showed the antibacterial effects of Cinnamomum plants. Secondary metabolites of Cinnamon plants have the ability to adhere to the microbial cell surface by crossing the lipid layer of the cytoplasmic wall, thus accumulating in the bacterial cell wall. Therefore, phytochemicals alter the structure of the membrane and increase its permeability, causing leakage of vital intracellular metabolites and, finally, cell death (Rhayour, 2003; Wu et al., 2009).

The bacterial cytoplasmic membrane plays a role in selective permeability by ensuring the crossing of H+ and K ions”. The maintenance and regulation of this barrier are provided by the structural, chemical composition of the cell wall. Increased ion leakage means a disruption of the permeability barrier. Cell metabolism can be influenced by changes in the structural integrity of the cell membrane that, in turn, can lead to the death of cells. (Cox et al., 2001).

Several preclinical experimental studies have been developed to highlight the antidiabetic effects of natural molecules from Cinnamomum species. Current conventional therapies used in the treatment of diabetes have many limitations, such as short- and long-term undesirable effects and high rates of failure (Sharifi-Rad et al., 2020a). Therefore, it is necessary to develop more effective drugs to treat diabetes. Presently, complementary herbal remedies are expected to have antihyperglycemic properties similar to those of conventional medications without troublesome side effects (Sharifi-Rad et al., 2020b). Traditional herbs and spices can also delay the onset of diabetic complications, control blood sugar levels and correct metabolic abnormalities. The in vitro methods are essentially based on the inhibition of enzymes involved in the carbohydrate catabolism and therefore sugar absorption. However, the determination of the in vivo antidiabetic activity requires the development of approaches such as oral glucose tolerance test, streptozotocin (SZT)-induced diabetes and alloxan-induced animal models.

The potential mechanisms of antidiabetic effects of Cinnamomum species were highlighted by recent studies. These have shown that secondary plant metabolites, such as terpenoids and flavonoids, have a significant hypoglycemic effect (Marles and Farnsworth, 1995). Terpenoids stimulate insulin secretion from pancreatic β-cells (Marles and Farnsworth, 1995) whereas cinnamaldehyde has a significantly anti-hyperglycemic effect (Subash Babu et al., 2007).

The antioxidant properties of Cinnamomum plants have extensively reported. Polar extracts of the leaves, fruits and seeds, as well as several pure compounds, exhibited relevant activities in a variety of antioxidant assays when compared to positive controls. Cinnamon extracts and its phenolic compounds
showed important free radical scavenging properties by the modulation of key enzymes implicated in oxidative stress or by modulation of oxidative pathways that influence the maintaining of redox homeostasis. Cinnamon extracts enhanced ferric reducing antioxidant power (FRAP) and plasma thiol (P-SH), and decreased MDA levels. In addition, they also increased antioxidant enzyme properties such as SOD and catalase (Moselhy and Ali, 2009; Roussel et al., 2009). Our study also showed that Cinnamomum derivatives have a good anti-inflammatoryatory properties.

The antitumor effects of Cinnamomum species have been reported by several studies (Koppikar et al., 2010; Kwon et al., 2010; Wondrak et al., 2010; Daker et al., 2013). These antineoplastic activities were tested in vitro on several types of human cancer cell lines. These studies highlighted the next possible anticancer mechanisms of Cinnamomum plants: 1) inhibition of tumor cells growth (Koppikar et al., 2010), 2) the cinnamon extract is a potent activator of the transcription factor NRF2 (nuclear factor erythroid 2-related factor 2) orchestrated antioxidant response in human cells (Wondrak et al., 2010), 3) cinnamaldehyde involves apoptosis mediated by the increase of p53 and APO-19 (Fas/CD95) protein signaling pathways (Ng and Wu, 2011), 4) DNA (deoxyribonucleic acid) damage (Ng and Wu, 2011), v) apoptosis mediated by the tyrosinase inhibition (Chen et al., 2007; Wang et al., 2011), 6) reducing the mitochondrial transmembrane potential, increasing the ratio of cytochrome C concentration and subsequently activated caspase-9/caspase-3 (Lin et al., 2009).

Recent studies showed neuroprotective effects of Cinnamomum plants and their derivatives. The aqueous extract of C. verum reduced tau aggregation and filament formation, the markers of Alzheimer’s disease (Peterson et al., 2009). From the brains of patients diagnosed with Alzheimer’s disease, the C. verum extract produced the complete disassembly of recombinant tau filaments and caused important alteration of the histology of paired helical filaments isolated, even though it was not deleterious to the normal cellular function of tau. (Peterson et al., 2009). Specifically, the proanthocyanidin, a chemical constituent isolated from the C. verum extract was observed to be mainly responsible for this inhibitory activity (Peterson et al., 2009).

Recent clinical studies have found that complementary herbal treatments with cinnamon regulate the frequency of menstrual cycles and may reduce insulin resistance in women with polycystic ovaries.

Regarding the toxicity data, some clinical studies reported that the most common adverse events after cinnamon consumption were gastrointestinal problems in patients with diabetes (Altschuler et al., 2007; Crawford, 2009), Helicobacter infection (Nir et al., 2000), polycystic ovarian syndrome (Kort and Lobo, 2014b) and seasonal allergies (Walanj et al., 2014). Dermatitis (Calnan, 1976; Ackermann et al., 2009; Isaac-Renton et al., 2015) and steatities (Miller et al., 1992; Endo and Rees, 2007) were also reported in some case reports. A systematic review of clinical trials and case reports/series on side effects associated with the use of cinnamon in humans indicated that no important difference obtained between cinnamon treated and control group in most cases (Food and Administration, 2005; Hajimofrednejad et al., 2018b).

Further efforts should be made to investigate future applications of standardized Cinnamomum plants using well-designed research.

OVERALL CONCLUSIONS

Cinnamomum plants, its extracts and chemical constituents have several activities promoting human health. Antibacterial, antidiabetic, antioxidant, anti-inflammatory, antitumor and neuroprotective activities are the most studied biological properties of Cinnamomum plants. Different from conventional therapeutic medicines, Cinnamomum species can be daily consumed in our diet without harmful effects and maybe used as a disease-preventive agent.

In general, chemical constituents of Cinnamomum plants such as cinnamon, cinnamaldehyde, cinnamophilin and others, have both direct and indirect activities, i.e. antioxidant and antibacterial activities occur by direct action on oxidant species or bacterial, whereas the antidiabetic, anticancer and anti-inflammatory activities occur indirectly via some yet undefined receptor-mediated mechanisms. In this present review, we have retrieved and summarized the wide applications and recent literature on the phytochemistry, bioactivity and pre-clinical and clinical investigations performed on many species of the genus. Besides, a detailed account on their toxicological considerations also indicate their safety and efficacy for human consumption. However, since a plethora of reports exist on the plant species, details on ethnobotany, biotechnological interventions and detailing structure-activity studies are beyond the scope and coverage of the present attempt.

Botanical research advances can improve the obtaining of Cinnamomum plants with the best phytochemical compounds. Moreover, the antimicrobial effects of Cinnamomum spp. can be potentiated in the food industry as the development of green foods.

AUTHOR CONTRIBUTIONS

JS-R, AD, and DC conceptualization. MM, AD, NK, SS, NE, and BH validation investigation. NC, CS, AB, and SV resources. BS, MM, AD, EV, and FL. VL, TG, AA, and CC. data curation. JS-R, AD, and DC conceptualization. MM, AD, NK, SS, NE, and BH validation investigation. NC, CS, AB, and SV resources. BS, MM, AD, EV, and FL. VL, TG, AA, and CC. data curation. JS-R, AD, FL, BS, VL, CC, and DC review and editing. DC supervision. All authors: writing. All authors read and approved the final version and contributed equally to the article.

FUNDING

This research and article processing charges were funded by a grant of Romanian Ministry of Research and Innovation, CCCI-UEFISCDI, (project number 61PCCDI/2018PN-III-P1-1.2-PCCDI-2017-0341), within PNCDI-III; CONICYT PIA/ APOYO CCTE AFB170007.
NF-Kb Activation: Effects upon lsb and Nrf2. Toxicol. Appl. Pharmacol. 229, 161–171. doi:10.1016/j.taap.2008.01.029
Liao, J.-C., Deng, J.-S., Chiu, C.-S., Hou, W.-C., Huang, S.-S., Shie, P.-H., et al. (2012a). Anti-inflammatory Activities of Cinnamomum cassia Constituents In Vitro and In Vivo. Evidence-Based Complement. Altern. Med. 2012, 429320. doi:10.1155/2012/429320
Liao, J.-C., Deng, J.-S., Chiu, C.-S., Hou, W.-C., Huang, S.-S., Shie, P.-H., et al. (2012b). Anti-Inflammatory Activities of Cinnamomum cassia Constituents In Vitro and In Vivo. Evid. Based Complement. Alternat. Med. 2012, 429320. doi:10.1155/2012/429320
Lin, C.-C., Wu, S.-J., Chang, C.-H., and Ng, L.-T. (2003). Antioxidant Activity of Cinnamon. J. Ethnopharmacology 83, 171–176. doi:10.1016/s0378-8741(03)00081-9
Miller, R. L., Gould, A. R., and Bernstein, M. L. (1992). Cinnamon-induced Hypoglycemia. Oral Surg. Oral Med. Oral Pathol. 74, 236–242. doi:10.1016/0030-4220(92)90015-5
Mang, B., Wolters, M., Schmitt, B., Kelb, K., Lichtinghagen, R., Stichtenoth, D. O., et al. (2006). Effects of a Cinnamon Extract on Plasma Glucose, HbA1c, and Inflammation in Subjects with Type 2 Diabetes. J. Clin. Oncol. 24, 520–528. doi:10.1200/jco.2004.11.043
Markman, M. (2002). Safety Issues in Using Complementary and Alternative Medicine. J. Clin. Oncol. 20, 395–415.
Markle, R. J., and Farnsworth, N. R. (1995). Anti-diabetic Plants and Their Active Constituents. Phytomedicine 2, 137–189. doi:10.1016/s0944-7113(11)80059-0
Mathew, S., and Abraham, T. E. (2006). Studies on the Antioxidant Activities of Cinnamon (Cinnamomum Verum) Bark Extracts, through Various In Vitro Models. Food Chem. 94, 520–528. doi:10.1016/j.foodchem.2004.11.043
Mbwoambo, Z. H., Moshi, M. J., Masimba, P. J., Kapingu, M. C., and Nondo, R. S. (2007). Antimicrobial Activity and Brine Shrimp Toxicity of Extracts of Terminalia Brandeia Brownii Roots and Stem. BMC Complement. Altern. Med. 7, 9. doi:10.1186/1472-6882-7-9
Miller, R. L., Gould, A. R., and Bernstein, M. L. (1992). Cinnamon-induced Stomatitis Venenata. Oral Surg. Oral Med. Oral Pathol. 73, 708–716. doi:10.1016/0030-4220(92)90016-1
Mishra, A., Bhatti, R., Singh, A., and Singh, I. S. (2010). Ameliorative Effect of the Cinnamon Oil fromCinnamomum Zeylanicum upon Early Stage Diabetic Nephropathy. Planta Med. 76, 412–417. doi:10.1055/s-0029-1186237
Moselhy, S. S., and Ali, H. K. (2009). Hepatoprotective Effect of Cinnamon Extracts against Carbon Tetrachloride Induced Oxidative Stress and Liver Injury in Rats. Biol. Res. 42, 93–98. doi:10.4067/s0716-97662009000100009
Ng, L. T., and Wu, S. J. (2011). Antiproliferative Activity of Cinnamomum cassia Constituents and Effects of Pifithrin-alpha on Their Apoptotic Signaling Pathways in Hep G2 Cells. Evid. Based Complement. Alternat. Med. 2011, 492148. doi:10.1093/ecam/nep220
Nihu, S. (2015). Department of Health and Human Services Herbs at a Glance. USA: Cinnamon NIH.
Nir, Y., Potasman, I., Stermer, E., Tabak, M., and Neeman, I. (2000). Controlled Trial of the Effect of Cinnamon Extract on Helicobacter pylori. Helicobacter 5, 94–97. doi:10.1046/j.1323-5378.2000.00014.x
Noudeh, G. D., Shariatzadeh, F., Noodeh, A. D., Mosha, F., Afzadi, M. A., Behravan, E., et al. (2010). Antitumor and Antibacterial Activity of Four Fractions from Helicomerium cinnamomum. J. Ethnopharmacology 129, 217–218. doi:10.1016/j.jep.2010.07.002
Ouali, M., Bentari, M., Zine, M., Belkhiri, T., and Benamara, B. (2010). Antioxidant Effect of Cinnamon Leaf Extracts on Spermatogenesis in Mice. J. Agric. Food Chem. 58, 427–433. doi:10.1021/jf903225p
Pamickar, K. S., Polansky, M. M., and Anderson, R. A. (2009). Cinnamon Polyphenols Attenuate Cell Swelling and Mitochondrial Dysfunction Following Oxygen-Glucose Deprivation in Glial Cells. Exp. Neurol. 216, 420–427. doi:10.1016/j.expneurol.2008.12.024
Pamickar, K. S., Polansky, M. M., Graves, D. J., Urban, J. F., and Anderson, R. A. (2012). A Procyanidin Type A Trimer from Cinnamon Extract Attenuates Glial Cell Swelling and the Reduction in Glutamate Uptake Following Ischemia-like Injury In Vitro. Neuroscience 202, 87–98. doi:10.1016/j.neuroscience.2011.11.052
Parseh, S., Shakerian, S., and Alizadeh, A. A. (2019). Effect of Chronic Aerobic/Anaerobic Exercise with Supplementation of Cinnamon on Insulin Resistance in Women with Polycystic Ovary Syndrome in Alzhev City in 2017. J. Arak Univ. Med. Sci. 22, 15–26.
Peng, X., Cheng, K.-W., Ma, J., Chen, B., Ho, C.-T., Lo, C., et al. (2008). Cinnamon Bark Proanthocyanidins as Reactive Carboxyl Scavengers to Prevent the Formation of Advanced Glycation Endproducts. J. Agric. Food Chem. 56, 1907–1911. doi:10.1021/jf073065v
Peterson, D. W., George, R. C., Saramacchino, F., Lapointe, N. E., Anderson, R. A., Graves, D. J., et al. (2009). Cinnamon Extract Inhibits Tau Aggregation Associated with Alzheimer’s Disease In Vitro. Jad 17, 585–597. doi:10.3233/jad-2009-1083
Prasad, K. N., Yang, B., Dong, X., Jiang, G., Zhang, H., Xie, H., et al. (2009). Flavonoid Contents and Antioxidant Activities from Cinnamomum Species. Innovative Food Sci. Emerging Techn. 10, 627–632. doi:10.1016/j.ifset.2009.05.009
Pyo, J.-H., Lee, J., Oh, Y., Kim, J., Seo, J., Lee, J.-H., Seo, J.-Y., Kim, S.-H., et al. (2013). Neuroprotective Effect of Trans-cinnamaldehyde on the 6-Hydroxydopamine-Induced Dopaminergic Injury. J. Pharmac. Biom. 36, 1928–1935. doi:10.1248/jpb.b13-00537
Qin, B., Panickar, K. S., and Anderson, R. A. (2014). Cinnamon Polyphenols Regulate S100β, Sirtuins, and Neuroactive Proteins in Rat C6 Glioma Cells. Nutrition 30, 210–217. doi:10.1016/j.nut.2013.07.001
Qin, B., Panickar, K. S., and Anderson, R. A. (2010). Cinnamon: Potential Role in the Prevention of Insulin Resistance, Metabolic Syndrome, and Type 2 Diabetes. J. Diabetes Sci. Technol. 4, 685–693. doi:10.1177/193229681000400324
Vallverdú-Queralt, A., Regueiro, J., Martínez-Huélamo, M., Rinaldi Alvarenga, Vallianou, N., Tsang, C., Taghizadeh, M., Davoodvandi, A., and Jafarnejad, S. (2019). Pharmacology | www.frontiersin.org May 2021 | Volume 12 | Article 600139

Tao, Y., Xu, X., Yan, J., and Cai, B. (2019). A Sensitive UPLC–MS/MS Method for Simultaneous Determination of Polyphenols in Rat Plasma: Application to a Pharmacokinetic Study of Dispensing Granules and Standard Decoction of Cinnamon cassia Twigs. Biomed. Chromatogr. 33, e5433. doi:10.1002/bmc.4534

Thompson, C., Davidson, P. M., Mahakarnchanakul, W., and Weiss, J. (2004). Thyme, Oregano, Cinnamon, Cumin and Bay. Food Chem. 1016/j.foodres.2012.06.016

Thongson, C., Davidson, P. M., Mahakarnchanakul, W., and Weiss, J. (2004). Thyme, Oregano, Cinnamon, Cumin and Bay. Food Chem. 1016/j.foodres.2012.06.016

Tsi, I.-L., Hung, C.-H., Duh, C.-Y., and Chen, I.-S. (2002). Cytotoxic Butanolides and Secobutanolides from the Stem Wood of Formosan Lindera Communis. Planta Med. 68, 142–145. doi:10.1055/s-2002-20260

Tsatsakis, A., Docea, A. O., Calina, D., Tsarouhas, K., Zam, D., et al. (2017). The Mechanistic and Pathophysiological Approach for Stroke Associated with Drugs of Abuse. Jem 8, 1295. doi:10.3390/jem8091295

Tsai, N., Tsai, N., and Lamuela-Raventos, R. M. (2014). A Comprehensive Study on the Phenolic Profiles of Widely Used Culinary Herbs and Spices: Rosemary, Oregano, Cinnamon, Cumin and Bay. Food Res. Int. 1016/j.foodres.2012.06.016

Van Loon, L. J. C. (2006). Cinnamon Supplementation Does Not Improve Glycemic Control in Postmenopausal Type 2 Diabetes Patients. J. Nutr. 136, 977–980. doi:10.1093/jn/136.4.977

Vivias, A. P. M., and Migliari, D. A. (2015). Cinnamon-induced Oral Mucosal Contact Reaction. Todont. 9, 257–259. doi:10.2174/187422101509010257

Wang, J.-M., Chen, C.-Y., and Zen, Z.-H. (2011). Identifying Melanogenesis Inhibitors from Cinnamon Subvenium with In Vitro and In Vivo Screening Systems by Targeting the Human Tyrosinase. Exp. Dermatol. 20, 242–248. doi:10.1111/j.1600-0625.2010.01611.x

Wang, J., Su, B., Jiang, H., Cui, N., Yu, Z., Yang, Y., et al. (2020). Traditional Uses, Phytochemistry and Pharmacological Activities of the Genus Cinnamomum (Lauraceae): A Review. Fitoterapia 146, 104675. doi:10.1016/j.fitote.2020.104675

Wang, R., Wang, R., and Yang, B. (2009). Extraction of Essential Oils from Five Cinnamon Leaves and Identification of Their Volatile Compound Compositions. Innovative Food Sci. Emerging Tech. 10, 289–292. doi:10.1016/j.ifset.2008.12.002

Wannissorn, B., Jarikasem, S., Siriwangchai, T., and Thubthimthed, S. (2005). Antibacterial Properties of Essential Oils from Thai Medicinal Plants. Fitoterapia 76, 233–236. doi:10.1016/j.fitote.2004.12.009

Wansi, S. L., Nyaduje, P., Ngamda, D., Mbuyo, E. P. N., Ngulefack, T. B., and Kamanyi, A. (2007). Blood Pressure Lowering Effect of the Ethanolic Extract from the Stem bark of Cinnamon Zeylanicum (Lauraceae) in Rats. Pharmacol. Online 3, 166–176.

Wild, S., Roglic, G., Green, A., Sicree, R., and King, H. (2004). Global Prevalence of Diabetes: Estimates for the Year 2000 and Projections for 2030. Diabetes Care 27, 1047–1053. doi:10.2337/diacare.27.5.1047

Wijekoon, B., and Susanto, C. A. (2017). The Effect of Metformin and Cinnamon on Serum Anti-mullerian Hormone in Women Having PCOS: A Double-Blind, Randomized, Controlled Trial. J. Hum. Reprod. Sci. 10, 31–36. doi:10.4103/jhrs.HRS_90_16

Worblin, L., Fry, H., Abraham, K., and Preiss-Weigert, A. (2010). Quantification of Flavoring Constituents in Cinnamon: High Variation of Courmarin in cassis Bark from the German Retail Market and in Authentic Samples from Indonesia. J. Agric. Food Chem. 58, 10568–10575. doi:10.1021/jf102112p

Wondrak, G., Villeneuve, N. F., Lamore, B. S., Ause, A. S., Jiang, T., and Zhang, D. D. (2010). The Cinnamon-Derived Dietary Factor Cinnamic Aldehyde Activates the Nrf2-dependent Antioxidant Response in Human Epithelial Colon Cells. Molecules 15, 3338–3355. doi:10.3390/molecules15053338

Wu, K., Lin, Y., Chai, X., Duan, X., Zhao, X., and Chum, C. (2019). Mechanisms of Vapour-phase Antibacterial Action of Essential Oil from Cinnamon Camphora Var. Linalofera Fujita against Escherichia coli. Food Sci. Nutr. 7, 2546–2555. doi:10.1002/fsn3.1104

Wu, V., Qiu, J., Delosreyes, B., Lin, C., and Pan, Y. (2009). Application of Cranberry Concentrate (Vaccinium Macrocarpon) to Control Escherichia coli O157:H7 in Ground Beef and its Antimicrobial Mechanism Related to the Downregulated Slp, hdeA and Cfa. Food Microbiol. 26, 32–38. doi:10.1016/j.fm.2008.07.014

Yanakiev, S. (2020). Effects of Cinnamon (Cinnamomum spp.) in Dentistry: A Review. Molecules 25, 3390. doi:10.3390/molecules25181484

Yap, P. S. X., Krishnan, T., Chan, K.-G., and Lim, S. H. E. (2015). Antibacterial Mode of Action of Cinnamonum Verum Bark Essential Oil, Alone and in

Frontiers in Pharmacology | www.frontiersin.org 26 May 2021 | Volume 12 | Article 600139

Cinnamomum Species
Combination with Piperacillin, against a Multi-Drug-Resistant Escherichia coli Strain. J. Microbiol. Biotechnol. 25, 1299–1306. doi:10.4014/jmb.1407.07054

Yeh, R.-Y., Shiu, Y.-L., Shei, S.-C., Cheng, S.-C., Huang, S.-Y., Lin, J.-C., et al. (2009). Evaluation of the Antibacterial Activity of Leaf and Twig Extracts of Stout Camphor Tree, Cinnamomum Kanehirae, and the Effects on Immunity and Disease Resistance of White Shrimp, Litopenaeus Vannamei. Fish Shellfish Immunol. 27, 26–32. doi:10.1016/j.fsi.2008.11.008

Yun, J.-W., You, J.-R., Kim, Y.-S., Kim, S.-H., Cho, E.-Y., Yoon, J.-H., et al. (2018). In vitro and In Vivo Safety Studies of Cinnamon Extract (Cinnamomum cassia) on General and Genetic Toxicology. Regul. Toxicol. Pharmacol. 95, 115–123. doi:10.1016/j.yrtph.2018.02.017

Zhang, J.-H., Liu, L.-Q., He, Y.-L., Kong, W.-J., and Huang, S.-A. (2010). Cytotoxic Effect of Trans-cinnamaldehyde on Human Leukemia K562 Cells. Acta Pharmacol. Sin 31, 861–866. doi:10.1038/aps.2010.76

Zhang, W., Xu, Y.-c., Guo, F.-j., Meng, Y., and Li, M.-l. (2008). Anti-diabetic Effects of Cinnamaldehyde and Berberine and Their Impacts on Retinol-Binding Protein 4 Expression in Rats with Type 2 Diabetes Mellitus. Chin. Med. J. 121, 2124–2128. doi:10.1097/00029330-200811010-00003

Zhao, J., and Ma, J.-S. (2016). Phytochemicals and Biological Activities of Genus Cinnamomum. Res. Rev. J. Pharmacognosy Phytochemistry 4, 27–34.

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Shariﬁ-Rad, Dey, Koirala, Shaheen, El Omari, Goloshvili, Cirone Silva, Bouyahya, Vitalini, Varoni, Martorell, Abdolshahi, Docea, Iriti, Calina, Les, López and Caruntu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.